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ABSTRACT 
Otitis media (OM) is the most common childhood bacterial infection, and leading cause 
of conductive hearing loss. Nontypeable Haemophilus influenzae (NTHi) is a major bacterial 
pathogen causing OM. During infection, epithelial cells act as the first line of defense by 
secreting numerous pro-inflammatory mediators including C-X-C motif chemokine ligand 5 
(CXCL5) and mucin 5AC (MUC5AC). While appropriate inflammatory responses are critical for 
the containment and removal of the invading pathogen, excess inflammation can lead to tissue 
damage, impaired mucociliary clearance and be detrimental to the host. Therefore, inflammatory 
responses must be tightly regulated. Current therapies for OM are ineffective due to the 
emergence of antibiotic-resistant NTHi strains and risk of side effects with prolonged use of 
immunosuppressant drugs. Therefore, therapeutic strategies that increase the levels of 
endogenous negative regulators of inflammation while leaving the positive pathways intact are 
gaining prominence. Thus, understanding the underlying molecular mechanisms regulating 
inflammation is critical for developing effective therapeutic strategies.
Despite the importance of CXCL5 chemokine in mediating inflammation, the signaling 
cascade mediating its up-regulation in OM remains largely unknown. Here we show that NTHi 
up-regulates CXCL5 expression by activating IKKβ-IκBα and p38 MAPK pathways via NF-κB 
nuclear translocation-dependent and -independent mechanism in middle ear epithelial cells. We 
also show that MKP-1 is a negative regulator of NTHi-induced CXCL5 expression. We further 
demonstrated the translational significance of these findings by reporting for the first time that 
curcumin, derived from Curcuma longa plant suppressed CXCL5 expression by direct inhibition 
of IKKβ phosphorylation, and inhibition of p38 MAPK via induction of negative regulator, 
MKP-1. Next, we show that curcumin also suppressed NTHi-induced MUC5AC expression via 
up-regulation of MKP-1, demonstrating for the first time the efficacy and pleiotropic anti-
inflammatory action of curcumin to suppress NTHi-induced inflammatory responses in OM 
model. Finally, we demonstrate for the first time that MKP-1 protein undergoes lysine 63 (K63)-
linked polyubiquitination, suggesting the importance of post-translational modification on MKP-
1 activity. We also show that curcumin enhanced K63-linked polyubiquitination of MKP-1. 
Since K63-linked polyubiquitination mediates non-degradative molecular functions such as 
protein-protein interactions, protein trafficking and regulation of signal transduction events, our 
findings suggest a new mechanism of action of curcumin on MKP-1. Taken together our study 
demonstrates the therapeutic potential of curcumin in treating NTHi-induced OM by modulating 
the expression and activity of negative regulator MKP-1. 
 
INDEX WORDS: Otitis media, Inflammation, Nontypeable Haemophilus influenzae, CXCL5, 
MUC5AC, Curcumin, MKP-1, Negative regulator, Post-translational modifications, 
Ubiquitination, K63-linked polyubiquitination 
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1 INTRODUCTION 
1.1 Nontypeable Haemophilus influenzae 
Haemophilus influenzae is a rod-shaped, non-motile, Gram-negative aerobic bacterium 
colonized in the nasopharynx of nearly 80% of the humans [1]. Unlike many other bacterial 
species, it is fastidious and requires both X-factor (hemin) and V-factor (nicotinamide adenine 
dinucleotide) for growth and proliferation [2]. Haemophilus influenzae are classified based on 
the composition of the polysaccharide capsule around the bacterium. Six encapsulated 
serological type strains (a-f) have been identified to date. These strains are associated with 
systemic diseases, such as bacteremia, meningitis [2]. The availability of a polysaccharide-
protein conjugate vaccine against the most virulent Haemophilus influenzae type b strain has 
nearly eliminated its associated diseases in developed countries [1].  
Additionally many strains lacking the polysaccharide capsule, termed nontypeable 
Hemophilus influenzae (NTHi) exist. While these strains are less virulent compared to 
encapsulated strains, the absence of the polysaccharide capsule makes it difficult to develop an 
effective vaccine [1, 3]. Respiratory tract infections associated with NTHi are one of the leading 
causes of morbidity and mortality in both developed and developing nations. NTHi is mainly 
identified as a respiratory pathogen and has been shown to predominantly target airway 
epithelium cells [2]. In vitro studies suggest that NTHi preferentially adheres to respiratory 
epithelial cells that either lack cilia or are structurally damaged. Many outer membrane proteins 
(OMPs) of NTHi can bind to the sialic acid-containing oligosaccharides of mucin in the 
nasopharynx, and initiate its colonization. NTHi evades host immune system due to type I IgA1 
protease that cleaves the host’s lysosome-associated membrane protein 1 [4]. NTHi does not 
possess any secretion system, which suggests its need to manipulate host pathways via 
	 2 
alternative mechanisms to invade and colonize the host [5]. Lack of reliance on any single 
mechanism of attachment and its ability to respond rapidly to host defense mechanisms by 
antigenic variation of OMPs, lipooligosaccharide (LOS) proteins, and enzymes make it harder to 
prevent, contain and treat NTHi infections.  
1.2 Otitis Media 
Otitis media (OM) is the most common childhood bacterial infection [6, 7] with more than 
700 million ear infections in the US each year. OM frequently leads to conductive hearing loss, 
affecting children during the crucial period of speech and language development [8, 9]. By age 3, 
nearly 90% of children have suffered from an episode of OM, resulting in approximately 30 
million doctor visits each year and 5 billion dollars in patient care. NTHi represents the cause of 
almost one-third episodes of OM. Streptococcus pneumoniae and Moraxella catarrhalis 
represent other bacterial causes of OM.  
OM occurrences are often preceded by a viral upper respiratory tract infection, which can 
cause swelling and congestion of the Eustachian tube [10]. This change in physiology not only 
results in the inability to equilibrate the pressure in between the nasopharynx and middle ear 
cavity but also leads to a decrease in the drainage of middle ear secretions. The collection of 
fluid in the middle ear cavity provides an ideal environment for the overgrowth of bacteria, such 
as NTHi. Children are particularly susceptible to OM due to the decreased length of the 
Eustachian tube as well as the insufficient function of its muscular opening [11]. Since the 
advent of pneumococcal vaccines (PCV7 and PCV13) NTHi-related OM has become most 
prevalent [12]. 
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1.3 Pathogenesis of bacterial OM 
Innate immunity is the dominant player in clearing middle ear infections. In response to 
antigenic stimuli, the middle ear triggers a rapid immune response of IgG in animal models, 
which leads to transudation of serum and leukocyte infiltration from the peripheral blood into the 
tympanic cavity. Adaptive immunity seems to be poorly sensitized by the invading pathogens at 
the middle ear side [13]. Therefore deficiencies in the components of innate immunity could lead 
to an increase in incidence, severity, and duration of OM [14]. While appropriate immune 
responses are critical for the containment and removal of the pathogens, excess inflammation can 
be detrimental to the host by causing tissue damage and perpetuating a never-ending cycle of 
immune responses [15-17]. OM is characterized by the presence of mucus overproduction, 
excess inflammation and impaired bacterial clearance in the middle ear. 
1.4 Inflammation 
Inflammation is the primary protective physiological response of the body against tissue 
injury, irritation, and infection from pathogens like bacteria, virus and the presence of foreign 
substances. It is triggered by the body’s first line of defense – innate immune system. The body 
responds to several of these stress stimuli by mounting an immune response, which involves the 
recruitment of leukocytes like macrophages, neutrophils in response to secreted cytokines and 
chemokines [18]. Inflammation is a double-edged sword characterized by five cardinal signs - 
swelling, redness, heat, pain and loss of function [19]. Following an injury or infection, the body 
initiates the healing/pathogen clearance via short-term acute inflammatory responses. Innate 
immunity is the first line of defense protecting the host until the sensitization required for 
eliciting adaptive immune responses in generated [20].  
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1.5 Pattern-recognition receptors in innate immunity 
The innate immune system recognizes conserved structures on pathogens; called 
pathogen-associated molecular patterns (PAMPs), through various pattern recognition receptors 
(PRRs) expressed on many immune and non-immune cells [20, 21]. Of the different classes of 
PRRs, Toll-like receptors (TLRs) have been widely studied for their role in triggering immune 
responses against invading pathogens. TLRs are type I transmembrane proteins with leucine-rich 
repeats in the ectodomain which recognizes PAMPs; a transmembrane domain; and intracellular 
Toll–interleukin 1 (IL-1) receptor (TIR) domain that propagates downstream signal transduction. 
To date, ten functional TLRs have been identified in humans. PAMPs recognized by TLRs 
include lipopolysaccharides (LPS), lipids, lipoproteins, peptidoglycans, proteins, and nucleic 
acids from bacteria, viruses, fungi and parasites [21]. TLRs can be categorized into two 
subgroups depending on their cellular localization. TLR1, TLR2, TLR4, TLR5, TLR6 and 
TLR11 are expressed on the cell surfaces, while TLR7, TLR8, and TLR9 are expressing in the 
intracellular vesicles such as endoplasmic reticulum (ER), endosomes, lysosomes and 
endolysosomes [22]. 
Upon recognition of corresponding PAMPs, TLRs recruits the TIR domain-containing 
adaptor protein myeloid differentiation factor 88 (MyD88). MyD88 then recruits and activates 
IL-1 receptor-associated kinases (IRAKs), which further lead to the recruitment and activation of 
tumor necrosis factor-receptor-associated factor 6 (TRAF6). IRAK-TRAF6 complex dissociates 
from the receptor bound complex and further interacts with transforming growth factor-b- 
activated kinase 1 (TAK1). Activation of TAK1 leads to initiation of further downstream 
signaling pathways. Phosphorylation and activation of inhibitor of kappa B kinases (IKKs) is one 
of the major pathways contributing to mounting an immune response. Phosphorylation and 
	 5 
proteasomal degradation of IkBa, by IKK, is necessary for activation of transcription factor 
nuclear factor kappa B (NF-κB). Additionally, activation of mitogen-activated protein kinases 
(MAPKs), p38, c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) 
also occurs. These pathways act independently or in concert resulting in nuclear translocation of 
transcription factors, which in turn regulates the expression of pro-inflammatory mediators [22]. 
1.6 Toll-like receptors in NTHi-induced OM 
NTHi contains several PAMPs that are recognized by many TLRs. Peptidoglycan and 
peptidoglycan-associated proteins such a P6 (an OMP) are recognized by TLR2 [23]. TLR2 
usually forms heterodimers with TLR1 or TLR6. TLR2-TLR1 heterodimer recognizes 
triacetylated lipopeptides, typical of Gram-negative bacteria, while TLR2-TLR6 heterodimer 
recognized diacetylated lipopetides, characteristic of Gram-positive bacteria [24, 25]. LOS can 
activate immune responses via both TLR2 and TLR4 [26]. Injection of peptidoglycan or LPS 
into chinchilla ear has shown to cause mucosal inflammation, neutrophil infiltration, edema, and 
abnormalities in middle ear pressure and macrophage infiltration into the sub-epithelial space 
[27]. While the immune responses to TLR ligands have been under study for decades, there is 
increasing evidence suggesting the role of TLRs itself in the pathogenesis of OM. 
NTHi induces TLR2 expression in middle ear epithelial cell lines. TLR2 activation leads to 
the expression of pro-inflammatory mediators. NTHi infection has been shown to induce 
expression of inflammatory mediators such as interleukin (IL)-1β, IL-8, CXCL5, and MUC5AC 
via TLR2 in middle ear epithelial cells [23, 28, 29]. Additionally, the appropriate functioning of 
TLRs is necessary for resolution of inflammatory responses. TLR deficiencies have been shown 
to cause significant abnormalities in recovery from infections [14]. Polymorphisms in TLRs and 
their co-receptor CD14 have been reported to increase susceptibility to OM in children [30].  
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1.7 Current Treatment and Challenges 
Treatment for OM can range in severity, from managing pain via oral analgesics and 
allowing the infection to subside independently to the use of antibiotics to actively combat the 
bacteria. The standard method of antibiotic treatment is the use of amoxicillin, beta-lactam [31]. 
However, since over 80% of NTHi strains are resistant to amoxicillin, the next regimen of 
treatment involves antibiotics such as trimethoprim, a dihydrofolate reductase inhibitor, and 
fluoroquinolones; inhibitors of DNA gyrase and topoisomerase [31, 32].  Decongestants, 
antihistamines, glucocorticoids have not found to be effective. Persistent, recurrent and chronic 
forms of OM affecting nearly 15% of the children poses a challenge regarding disease 
management. Prophylactic usage of antibiotics has minimal effect of resolving chronic OM and 
has led to the emergence of multi-drug resistant bacterial strains. In severe cases, tympanostomy 
tubes are placed to drain the accumulation of fluid in the middle ear [33]. Prolonged usage of 
these treatments poses severe risks due to serious side effects, weakened immune system and 
otorrhea (discharge from ear). Development of NTHi vaccine remains a challenge due to the 
high genetic diversity of NTHi strains and high antigenic variability of surface-exposed antigens 
[34, 35]. Therefore there is an urgent need for developing alternate therapeutic strategies for 
treating OM, based on full understanding of the molecular signaling pathways leading to its 
pathogenesis. 
1.8 Inflammatory mediators in OM 
1.8.1 C-X-C chemokine CXCL5 
CXCL5/ENA-78 (epithelial neutrophil-activating peptide 78) of the Glu-Leu-Arg (ELR) 
motif-containing C-X-C chemokine family is critical for recruiting neutrophils in response to 
bacterial infections [36]. Epithelial-cell derived CXCL5 is vital in polymorphonuclear leukocytes 
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(PMN)-driven destructive inflammatory responses in Mycobacterium tuberculosis-induced 
pulmonary tuberculosis. Cxcl5-/- mice were found to be resistant to fatal tuberculosis [37]. The 
role of CXCL5 in neutrophil trafficking in lipopolysaccharide (LPS)-induced lung inflammation 
in mice has been reported [38]. A recent study demonstrated that LPS-induced deregulated 
CXCL5 expression resulted in exaggerated neutrophil-mediated inflammation in pulmonary 
bronchiolar cells [39]. CXCL5 is also involved in angiogenesis, tumor growth, and metastasis 
[40], with CXCL5 overexpression leading to poor survival in cancer patients [41]. Affymetrix 
chip analysis on mouse genome revealed marked up-regulation of CXCL5 expression by NTHi 
in the middle ear of mouse [42]. Middle ear effusion samples from patients with acute and 
chronic OM have shown the presence of viable NTHi trapped within neutrophil extracellular 
traps, which continued to elicit inflammatory responses [43, 44]. While the appropriate 
neutrophil response is critical for the removal of the invading pathogen, excess inflammation can 
lead to tissue damage and perpetuate inflammation leading to detrimental effects, as seen across 
several inflammatory pathologies including OM [15-17, 45]. Thus, these findings suggest that 
therapeutic strategies to control aberrant CXCL5 production are of utmost importance for 
modulating inflammation in OM. 
1.8.2 MUC5AC mucin 
Mucin glycoproteins are a major component of mucus secretions in the middle ear, 
trachea, digestive and reproductive tracts. Mucus production represents a protective innate 
defense mechanism to protect and lubricate the epithelium and trap invading pathogens for 
removal by the mucociliary clearance system [46]. However, in chronic infections, excess mucin 
impairs the mucociliary clearance system, resulting in mucus accumulation and defective 
function of the mucus-lined epithelial tracts. Of the ~24 mucin genes identified till date 
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MUC5AC mucin has been shown to play a critical role in the pathogenesis of upper respiratory 
tract infections including OM [47, 48]. In patients with OM, increased mucus effusion into the 
ear’s tympanic cavity impairs the movement of the eardrum and middle ear bones and leads to 
hearing problems. A higher concentration of mucin in the middle ear effusion has been shown to 
correlate with the extent of hearing impairment [9, 49]. While mucin up-regulation is an 
important innate defense response of the host to contain infections in the middle ear, excess 
mucin can lead to impaired mucociliary clearance and hearing loss [47]. Therefore mucin 
expression must be tightly controlled.    
1.9 Negative Regulation of NTHi-induced TLR signaling pathways 
While mounting an appropriate inflammatory response against invading microbial 
pathogens is critical for the survival of the host, deregulated overactive inflammatory responses 
are detrimental to the host. Therefore, TLR signaling pathways must be tightly regulated to 
maintain immune balance by negative regulation. Negative regulation of TLRs has been reported 
to occur via numerous mechanisms at multiple levels of the signal transduction.  
1.9.1 Mechanism of negative regulation of TLR signaling 
The negative regulatory mechanisms can be broadly categorized into three groups.  
i. Degradation of signal proteins. Degradation of signal transduction components is one of 
the principal mechanisms to inhibit any signaling pathway. The addition of a 76-amino acid 
containing ubiquitin molecule to a protein tags the protein for degradation by the 26S 
proteasome. Triad domain containing protein 3 (Triad3A) is an E3 ubiquitin ligase that 
enhances the ubiquitination of TLRs. Suppressor of cytokine signaling (SOCS-1) induces 
polyubiquitination of TIR domain-containing MyD88-adaptor like protein (MAL). In 
addition to proteasomal degradation, protein degradation by lysosomes is also known to 
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contribute to negative regulation of TLR signaling. Tripartite-motif protein 30a (Trim 30a) 
is a negative regulator of TLR-mediated NF-κB activation by targeting TAK1 binding 
protein (TAB) TAB2 and TAB3 for lysosomal protein degradation [50, 51]. 
ii. Transcriptional regulation. Recruitment of histone deacetylase (HDAC) to the promoter 
regions of proinflammatory cytokines, represses transcription of these cytokines by blocking 
access to the transcriptional machinery. Cyclic AMP-dependent transcription factor (ATF3) 
recruits HDAC1 to the promoter regions of IL-12p40, IL-6, and TNF-α genes, thereby 
repressing their transcription. Non-coding RNAs, including microRNAs (miRNAs), have 
emerged as fine tuners of TLR signaling by targeting mRNAs of pro-inflammatory cytokines 
for miRNA-mediated gene silencing by promoting mRNA degradation [51]. 
iii. Dissociation of adaptor proteins. TLRs can identify different pathogens and activate 
appropriate signaling pathways. The specificity of the activated pathway depends on the TIR 
domain-containing adaptor proteins such as MyD88, MAL, TIR domain -containing adaptor 
protein-inducing IFN-β (TRIF), TRAM being recruited to the TLR. Sterile alpha and 
Armadillo motif containing protein (SARM) is a TIR domain-containing protein is a negative 
regulator of TRIF-dependent TLR signaling. SARM competes with TRIF to associate with 
TLR. IFN-regulatory factor (IRF) family of transcription factors; IRF-5 and IRF-7 interact 
with MyD88 to induce expression of proinflammatory mediators. IRF-4 competes with IRF-5 
and IRF-7 to bind with MyD88. IRF-4 binding to MyD88 suppresses cytokine expression. A 
splicing isoform of MyD88, MyD88s is a negative regulator of TLR signaling. MyD88s is 
recruited to TLR via its TIR-domain. However, due to the lack of death domain (DD) in 
MyD88s, subsequent recruitment of IRAK-4 and activation of IRAK-1 fails to occur, thereby 
blocking the transmission of activating stimuli [50]. Post-translational modifications (PTMs) 
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such as phosphorylation, acetylation, ubiquitination, SUMOylation also play critical roles in 
signal transduction by regulating the interactions between adaptor proteins [51]. Upon TLR 
stimulation, activated IRAKs interact with TNF-receptor association factor (TRAF) 6 
resulting in polyubiquitination (ubiquitin protein conjugated at lysine 63 (K63)), that lead to 
phosphorylation and activation of the IKK and MAPKs. Tumor suppressor cylindromatosis 
(CYLD) is a deubiquitinase that cleaves K63 linked polyubiquitin chains, on TRAF2, 
TRAF6, TRAF7 and IKKγ, thereby suppressing TLR signal transduction [52]. MAPK 
activation is mainly regulated by MAPK phosphatases (MKPs), comprising of 10 dual-
specificity phosphatases (DUSPs) that dephosphorylate p38, ERK, JNK MAPKs [53]. MKP-
1-/- macrophages produce excess amounts of pro-inflammatory mediators. MKP-1 deficiency 
increases the susceptibility of mice to endotoxic shock [54]. Aberrant innate immune 
responses in MKP-1-/- mice highlight the importance of MKP-1 in the negative regulation of 
TLR signaling [55]. 
1.9.2 MKP-1 
MKP-1 belongs to a subfamily of the larger DUSP family, which specifically 
dephosphorylates the threonine and tyrosine residues within the signature motif T-X-Y present in 
the activation loop of MAPKs. MKP-1 consists of an N-terminal non-catalytic domain and a C-
terminal catalytic domain. MKP-1 binds to its substrate MAPK via the kinase interacting motif 
(KIM) present within the N-terminal domain [56].  
1.9.3 MKP-1 regulation 
1.9.3.1 Transcriptional Regulation 
MKP-1 expression is induced at both mRNA and protein by many mitogens and stress 
mediators via TLR activation [57]. An increase in MKP-1 levels correlates with a decrease in 
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p38 and JNK signaling pathways. TLR induces MKP-1 expression via recruiting both MyD88 
and TRIF adaptor proteins [57]. p38, ERK, and JNK MAPKs have been shown to mediate TLR-
induced MKP-1 expression. Additionally, several immunosuppressive agents such as 
glucocorticoids, phosphodiesterase (PDE) inhibitors, vinpocetine, resveratrol mediate their 
inhibitory effects via MKP-1 [58-61]. These agents inhibit inflammation by inducing MKP-1 
expression, which would, in turn, inhibit MAPK activation, thereby suppressing inflammation. 
Anti-inflammatory cytokines such a transforming growth factor-β (TGF-β) and IL-10 have also 
been shown to increase MKP-1 expression [62, 63]. Thus, MKP-1 up-regulation seems to be a 
major mechanism for negative regulation of TLR signaling. 
1.9.3.2 Post-translational modifications of MKP-1 
In addition to transcriptional up-regulation of MKP-1 expression, PTMs that increase the 
stability and activity of MKP-1 and its affinity to MAPK substrates have been widely reported.  
Phosphorylation. Transient activation of ERK leads to phosphorylation of MKP-1 at the C-
terminal Ser359, and Ser364 increasing its stability without altering its phosphatase activity [64]. 
However, prolonged activation of ERK results in phosphorylation of Ser296 and Ser323 
residues, promoting MKP-1 interaction with E3 ubiquitin ligase Skp-cullin-F-box, which targets 
MKP-1 for proteasomal degradation [65, 66].  
Oxidation. Reactive oxygen species (ROS)-induced oxidation of Cys258 residue in the C-
terminal of MKP-1 resulted in a decrease in phosphatase activity. This phenomenon was 
observed in TNF-α induced sustained activation of JNK in NF-κB deficient cells. MKP-1 
inactivation leads to prolonged activation of JNK, leading to apoptosis. Thus MKP-1 oxidation is 
detrimental to the survival of the host [64]. 
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Acetylation. MKP-1 has been reported to undergo acetylation at Lys57 within the KIM, in 
response to TLR stimulation. Acetylation of MKP-1 did not affect its intrinsic phosphatase 
activity. However, acetylated MKP-1 demonstrated increased affinity to p38 MAPK substrate, 
resulting in an indirect increase in MKP-1 activity [67]. Thus, MKP-1 acetylation inhibits TLR 
signaling. 
1.10 Curcumin - an alternative therapeutic strategy for regulating inflammation in OM 
1.10.1 Phytochemicals as potential anti-inflammatory drugs 
Current anti-inflammatory therapies act via suppressing the positive signaling pathways 
involved in the production of inflammatory mediators.  However, prolonged use of these drugs 
could have severe side effects because these pathways are also involved in mediating 
physiological responses. Therefore, therapeutic strategies that increase the levels of endogenous 
negative regulators of inflammation while leaving the positive pathways intact are gaining 
prominence [51]. In this regard, plant-based phytochemicals are gaining prominence for their 
minimal side effects even with prolonged usage. We previously showed that vinpocetine an 
alkaloid extracted from the periwinkle plant inhibits TNF-α and LPS induced up-regulation of 
proinflammatory mediators via inhibition of NF-κB signaling [68]. We also demonstrated that 
vinpocetine also suppressed mucus overproduction by up-regulating the negative regulator MKP-
1, thereby inhibiting MAPK activation [59]. Vinpocetine is currently available as a dietary 
supplement. Another study from our lab showed that resveratrol, a non-flavenoid polyphenolic 
compound found in berries and grapes has anti-inflammatory properties. Resveratrol suppressed 
NTHi-induced inflammation by up-regulating the negative regulator MyD88s, which would in 
turn inhibit TLR signaling. Resveratrol is also available as a daily supplement [58].  
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1.10.2 Curcumin 
Curcumin, a polyphenol derived from the rhizome of Curcuma longa plant was long-
used for its medicinal properties [69]. Curcumin has been widely reported to have anti-
inflammatory, anti-oxidant, anti-microbial, anti-diabetic, anti-carcinogenic anti-tumorigenic, 
anti-amyloidogenic effects. Due to its tolerability and non-toxicity at high doses, curcumin could 
be used for prolonged periods without any side effects [69]. Completed clinical trials revealed 
promising therapeutic effects of curcumin in patients with cancer, inflammatory bowel disease, 
irritable bowel disease, rheumatoid arthritis, Alzheimer’s disease, and diabetes [70-76]. More 
clinical trials evaluating the efficacy of curcumin on a broad range of inflammatory conditions 
are currently underway. Despite it’s widely known potent anti-inflammatory properties; the 
effect of curcumin on NTHi-induced inflammatory responses remains to be understood. 
1.11 Significance 
NTHi represents the cause of approximately one-third episodes of OM. Current 
treatments for bacterial OM rely on the systemic use of antibiotics, which often leads to the 
emergence of multi-drug resistant bacterial strains. Development of NTHi vaccine remains a 
challenge due to the high genetic diversity of NTHi strains and high antigenic variability of 
surface-exposed antigens. Therefore, there is an urgent need for developing alternate therapeutic 
strategies for treating NTHi infections. Additionally current anti-inflammatory therapies act via 
suppressing the positive signaling pathways involved in the production of inflammatory 
mediators.  However, prolonged use of these drugs could have severe side effects because these 
pathways are also involved in mediating physiological responses. Therefore, therapeutic 
strategies that increase the levels of endogenous negative regulators of inflammation while 
leaving the positive pathways intact are gaining prominence Thus, identifying the underlying 
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molecular mechanisms leading to up-regulation of inflammation is critical in the quest for novel 
therapeutic strategies with increased specificity and reduced side effects. Though curcumin has 
been long known as an anti-inflammatory agent, its effect on modulating NTHi-induced 
inflammatory responses in OM remains to be evaluated. 
We performed this study to test the hypothesis that curcumin suppresses NTHi-induced 
expression of inflammatory mediators: chemokine CXCL5 and mucin MUC5AC in OM model. 
We tested this hypothesis in the following chapters. In chapter 2 we, (i) identified the molecular 
mechanism involved in the up-regulation of NTHi-induced CXCL5 chemokine expression (ii) 
demonstrated the inhibitory effect of curcumin on CXCL5 expression and (iii) identified the 
negative regulator MKP-1 as the key signaling molecule mediating the inhibitory effect of 
curcumin on CXCL5 expression. In chapter 3, we extended the findings observed from the 
CXCL5 studies to examine the effect of curcumin on MUC5AC mucin expression. In chapter 4, 
we further evaluated the effect of curcumin on promoting MKP-1 activity, by demonstrating that 
curcumin enhanced the post-translational K63-linked polyubiquitination of MKP-1, which could 
in turn enhance MKP-1 activity. Thus the insights from this study will help develop alternative 
therapies for treating NTHi-induced OM. 
1.12 References 
1. Foxwell, A.R., J.M. Kyd, and A.W. Cripps, Nontypeable Haemophilus influenzae: 
pathogenesis and prevention. Microbiol Mol Biol Rev, 1998. 62(2): p. 294-308. 
2. King, P.T. and R. Sharma, The Lung Immune Response to Nontypeable Haemophilus 
influenzae (Lung Immunity to NTHi). J Immunol Res, 2015. 2015: p. 706376. 
3. Erwin, A.L. and A.L. Smith, Nontypeable Haemophilus influenzae: understanding 
virulence and commensal behavior. Trends Microbiol, 2007. 15(8): p. 355-62. 
	 15 
4. St Geme, J.W., 3rd, M.L. de la Morena, and S. Falkow, A Haemophilus influenzae IgA 
protease-like protein promotes intimate interaction with human epithelial cells. Mol 
Microbiol, 1994. 14(2): p. 217-33. 
5. Clementi, C.F. and T.F. Murphy, Non-typeable Haemophilus influenzae invasion and 
persistence in the human respiratory tract. Front Cell Infect Microbiol, 2011. 1: p. 1. 
6. Giebink, G.S., Immunoprophylaxis of otitis media. Advances in experimental medicine 
and biology, 1991. 303: p. 149-58. 
7. Bluestone, C.D., Otitis media in children: to treat or not to treat? The New England 
journal of medicine, 1982. 306(23): p. 1399-404. 
8. Bluestone, C.D., Chronic otitis media with effusion. Pediatric infectious disease, 1982. 
1(3): p. 180-7. 
9. Reichman, J. and W.C. Healey, Learning disabilities and conductive hearing loss 
involving otitis media. Journal of learning disabilities, 1983. 16(5): p. 272-8. 
10. Bhutta, M.F., Epidemiology and pathogenesis of otitis media: construction of a 
phenotype landscape. Audiol Neurootol, 2014. 19(3): p. 210-23. 
11. Heikkinen, T. and T. Chonmaitree, Importance of respiratory viruses in acute otitis 
media. Clin Microbiol Rev, 2003. 16(2): p. 230-41. 
12. Gilsdorf, J.R., What the pediatrician should know about non-typeable Haemophilus 
influenzae. J Infect, 2015. 71 Suppl 1: p. S10-4. 
13. Ryan, A.F., et al., The effect of complement depletion on immunologically mediated 
middle ear effusion and inflammation. Clin Immunol Immunopathol, 1986. 40(3): p. 410-
21. 
	 16 
14. Leichtle, A., et al., Innate signaling in otitis media: pathogenesis and recovery. Curr 
Allergy Asthma Rep, 2011. 11(1): p. 78-84. 
15. Butterfield, T.A., T.M. Best, and M.A. Merrick, The dual roles of neutrophils and 
macrophages in inflammation: a critical balance between tissue damage and repair. J Athl 
Train, 2006. 41(4): p. 457-65. 
16. Kruger, P., et al., Neutrophils: Between host defence, immune modulation, and tissue 
injury. PLoS Pathog, 2015. 11(3): p. e1004651. 
17. Nathan, C. and A. Ding, Nonresolving inflammation. Cell, 2010. 140(6): p. 871-82. 
18. Medzhitov, R., Origin and physiological roles of inflammation. Nature, 2008. 454(7203): 
p. 428-35. 
19. Lawrence, T., D.A. Willoughby, and D.W. Gilroy, Anti-inflammatory lipid mediators 
and insights into the resolution of inflammation. Nat Rev Immunol, 2002. 2(10): p. 787-
95. 
20. Medzhitov, R. and C. Janeway, Jr., Innate immunity. N Engl J Med, 2000. 343(5): p. 
338-44. 
21. Akira, S., K. Takeda, and T. Kaisho, Toll-like receptors: critical proteins linking innate 
and acquired immunity. Nat Immunol, 2001. 2(8): p. 675-80. 
22. Kawai, T. and S. Akira, The role of pattern-recognition receptors in innate immunity: 
update on Toll-like receptors. Nat Immunol, 2010. 11(5): p. 373-84. 
23. Shuto, T., et al., Activation of NF-kappa B by nontypeable Hemophilus influenzae is 
mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha /beta-I kappa B alpha 
and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc Natl Acad Sci 
U S A, 2001. 98(15): p. 8774-9. 
	 17 
24. Jin, M.S., et al., Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a 
tri-acylated lipopeptide. Cell, 2007. 130(6): p. 1071-82. 
25. Kang, J.Y., et al., Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like 
receptor 6 heterodimer. Immunity, 2009. 31(6): p. 873-84. 
26. Trinchieri, G. and A. Sher, Cooperation of Toll-like receptor signals in innate immune 
defence. Nat Rev Immunol, 2007. 7(3): p. 179-90. 
27. Leake, E.R., et al., Peptidoglycan isolated from nontypeable Haemophilus influenzae 
induces experimental otitis media in the chinchilla. J Infect Dis, 1994. 170(6): p. 1532-8. 
28. Konduru, A.S., B.C. Lee, and J.D. Li, Curcumin suppresses NTHi-induced CXCL5 
expression via inhibition of positive IKKbeta pathway and up-regulation of negative 
MKP-1 pathway. Sci Rep, 2016. 6: p. 31695. 
29. Wang, W.Y., et al., CYLD negatively regulates nontypeable Haemophilus influenzae-
induced IL-8 expression via phosphatase MKP-1-dependent inhibition of ERK. PLoS 
One, 2014. 9(11): p. e112516. 
30. Emonts, M., et al., Genetic polymorphisms in immunoresponse genes TNFA, IL6, IL10, 
and TLR4 are associated with recurrent acute otitis media. Pediatrics, 2007. 120(4): p. 
814-23. 
31. Arguedas, A., et al., Otitis media across nine countries: disease burden and management. 
Int J Pediatr Otorhinolaryngol, 2010. 74(12): p. 1419-24. 
32. Ito, M., et al., Clonal spread of beta-lactamase-producing amoxicillin-clavulanate-
resistant (BLPACR) strains of non-typeable Haemophilus influenzae among young 
children attending a day care in Japan. Int J Pediatr Otorhinolaryngol, 2010. 74(8): p. 
901-6. 
	 18 
33. Rettig, E. and D.E. Tunkel, Contemporary concepts in management of acute otitis media 
in children. Otolaryngol Clin North Am, 2014. 47(5): p. 651-72. 
34. Poolman, J.T., et al., Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. 
Vaccine, 2000. 19 Suppl 1: p. S108-15. 
35. van Alphen, L., et al., Differences in genetic diversity of nonecapsulated Haemophilus 
influenzae from various diseases. Microbiology, 1997. 143 ( Pt 4): p. 1423-31. 
36. Charo, I.F. and R.M. Ransohoff, The many roles of chemokines and chemokine receptors 
in inflammation. N Engl J Med, 2006. 354(6): p. 610-21. 
37. Nouailles, G., et al., CXCL5-secreting pulmonary epithelial cells drive destructive 
neutrophilic inflammation in tuberculosis. J Clin Invest, 2014. 124(3): p. 1268-82. 
38. Jeyaseelan, S., et al., Induction of CXCL5 during inflammation in the rodent lung 
involves activation of alveolar epithelium. Am J Respir Cell Mol Biol, 2005. 32(6): p. 
531-9. 
39. Gibbs, J., et al., An epithelial circadian clock controls pulmonary inflammation and 
glucocorticoid action. Nat Med, 2014. 20(8): p. 919-26. 
40. Zhou, S.L., et al., CXCL5 contributes to tumor metastasis and recurrence of intrahepatic 
cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils. Carcinogenesis, 
2014. 35(3): p. 597-605. 
41. Li, A., et al., Overexpression of CXCL5 is associated with poor survival in patients with 
pancreatic cancer. Am J Pathol, 2011. 178(3): p. 1340-9. 
42. MacArthur, C.J., et al., Otitis media impacts hundreds of mouse middle and inner ear 
genes. PLoS One, 2013. 8(10): p. e75213. 
	 19 
43. Thornton, R.B., et al., Neutrophil extracellular traps and bacterial biofilms in middle ear 
effusion of children with recurrent acute otitis media--a potential treatment target. PLoS 
One, 2013. 8(2): p. e53837. 
44. King, L.B., Observation of Viable Nontypeable Haemophilus Influenzae Bacteria 
              within Neutrophil Extracellular Traps in Clinical Samples from Chronic 
              Otitis Media. Otolaryngology, 2013. 3(145). 
45. Segel, G.B., M.W. Halterman, and M.A. Lichtman, The paradox of the neutrophil's role 
in tissue injury. J Leukoc Biol, 2011. 89(3): p. 359-72. 
46. Knowles, M.R. and R.C. Boucher, Mucus clearance as a primary innate defense 
mechanism for mammalian airways. J Clin Invest, 2002. 109(5): p. 571-7. 
47. Kerschner, J.E., Mucin gene expression in human middle ear epithelium. Laryngoscope, 
2007. 117(9): p. 1666-76. 
48. Kerschner, J.E., et al., MUC5AC expression in human middle ear epithelium of patients 
with otitis media. Arch Otolaryngol Head Neck Surg, 2010. 136(8): p. 819-24. 
49. Majima, Y., et al., Hearing impairment in relation to viscoelasticity of middle ear 
effusions in children. Ann Otol Rhinol Laryngol, 1988. 97(3 Pt 1): p. 272-4. 
50. Wang, J., et al., Negative regulation of Toll-like receptor signaling pathway. Microbes 
Infect, 2009. 11(3): p. 321-7. 
51. Kondo, T., T. Kawai, and S. Akira, Dissecting negative regulation of Toll-like receptor 
signaling. Trends Immunol, 2012. 33(9): p. 449-58. 
52. Wang, W.Y., J.H. Lim, and J.D. Li, Synergistic and feedback signaling mechanisms in 
the regulation of inflammation in respiratory infections. Cell Mol Immunol, 2012. 9(2): p. 
131-5. 
	 20 
53. Owens, D.M. and S.M. Keyse, Differential regulation of MAP kinase signalling by dual-
specificity protein phosphatases. Oncogene, 2007. 26(22): p. 3203-13. 
54. Zhao, Q., et al., MAP kinase phosphatase 1 controls innate immune responses and 
suppresses endotoxic shock. J Exp Med, 2006. 203(1): p. 131-40. 
55. Chi, H. and R.A. Flavell, Acetylation of MKP-1 and the control of inflammation. Sci 
Signal, 2008. 1(41): p. pe44. 
56. Caunt, C.J. and S.M. Keyse, Dual-specificity MAP kinase phosphatases (MKPs): shaping 
the outcome of MAP kinase signalling. FEBS J, 2013. 280(2): p. 489-504. 
57. Chi, H., et al., Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK 
phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci U S A, 2006. 
103(7): p. 2274-9. 
58. Andrews, C.S., et al., Resveratrol suppresses NTHi-induced inflammation via up-
regulation of the negative regulator MyD88 short. Sci Rep, 2016. 6: p. 34445. 
59. Lee, J.Y., et al., Vinpocetine inhibits Streptococcus pneumoniae-induced upregulation of 
mucin MUC5AC expression via induction of MKP-1 phosphatase in the pathogenesis of 
otitis media. J Immunol, 2015. 194(12): p. 5990-8. 
60. Komatsu, K., et al., Glucocorticoids inhibit nontypeable Haemophilus influenzae-induced 
MUC5AC mucin expression via MAPK phosphatase-1-dependent inhibition of p38 
MAPK. Biochem Biophys Res Commun, 2008. 377(3): p. 763-8. 
61. Lee, J., et al., Phosphodiesterase 4B mediates extracellular signal-regulated kinase-
dependent up-regulation of mucin MUC5AC protein by Streptococcus pneumoniae by 
inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway. J Biol Chem, 
2012. 287(27): p. 22799-811. 
	 21 
62. Hammer, M., et al., Control of dual-specificity phosphatase-1 expression in activated 
macrophages by IL-10. Eur J Immunol, 2005. 35(10): p. 2991-3001. 
63. Xiao, Y.Q., et al., Cross-talk between ERK and p38 MAPK mediates selective 
suppression of pro-inflammatory cytokines by transforming growth factor-beta. J Biol 
Chem, 2002. 277(17): p. 14884-93. 
64. Brondello, J.M., J. Pouyssegur, and F.R. McKenzie, Reduced MAP kinase phosphatase-1 
degradation after p42/p44MAPK-dependent phosphorylation. Science, 1999. 286(5449): 
p. 2514-7. 
65. Lin, Y.W., S.M. Chuang, and J.L. Yang, ERK1/2 achieves sustained activation by 
stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway. J 
Biol Chem, 2003. 278(24): p. 21534-41. 
66. Lin, Y.W. and J.L. Yang, Cooperation of ERK and SCFSkp2 for MKP-1 destruction 
provides a positive feedback regulation of proliferating signaling. J Biol Chem, 2006. 
281(2): p. 915-26. 
67. Cao, W., et al., Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits 
Toll-like receptor signaling. J Exp Med, 2008. 205(6): p. 1491-503. 
68. Jeon, K.I., et al., Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-
dependent but PDE-independent mechanism. Proc Natl Acad Sci U S A, 2010. 107(21): 
p. 9795-800. 
69. Gupta, S.C., et al., Discovery of curcumin, a component of golden spice, and its 
miraculous biological activities. Clin Exp Pharmacol Physiol, 2012. 39(3): p. 283-99. 
	 22 
70. Bundy, R., et al., Turmeric extract may improve irritable bowel syndrome symptomology 
in otherwise healthy adults: a pilot study. J Altern Complement Med, 2004. 10(6): p. 
1015-8. 
71. Deodhar, S.D., R. Sethi, and R.C. Srimal, Preliminary study on antirheumatic activity of 
curcumin (diferuloyl methane). Indian J Med Res, 1980. 71: p. 632-4. 
72. Durgaprasad, S., et al., A pilot study of the antioxidant effect of curcumin in tropical 
pancreatitis. Indian J Med Res, 2005. 122(4): p. 315-8. 
73. Epstein, J., et al., Curcumin suppresses p38 mitogen-activated protein kinase activation, 
reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of 
children and adults with inflammatory bowel disease. Br J Nutr, 2010. 103(6): p. 824-32. 
74. Ringman, J.M., et al., A potential role of the curry spice curcumin in Alzheimer's disease. 
Curr Alzheimer Res, 2005. 2(2): p. 131-6. 
75. Sharma, R.A., et al., Pharmacodynamic and pharmacokinetic study of oral Curcuma 
extract in patients with colorectal cancer. Clin Cancer Res, 2001. 7(7): p. 1894-900. 
76. Srinivasan, M., Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J 
Med Sci, 1972. 26(4): p. 269-70. 
 
 
 
 
 
	 23 
2 CURCUMIN SUPPRESSES NTHI-INDUCED CXCL5 EXPRESSION VIA 
INHIBITION OF POSITIVE IKKΒ PATHWAY AND UP-REGULATION OF 
NEGATIVE MKP-1 PATHWAY 
 
Publication: Anuhya S Konduru, Byung-Cheol Lee, Jian-Dong Li* 
Copyright © Scientific Reports August 2016 
 
2.1 Abstract 
Otitis media (OM) is the most common childhood bacterial infection, and leading cause 
of conductive hearing loss. Nontypeable Haemophilus influenzae (NTHi) is a major bacterial 
pathogen for OM. OM characterized by the presence of overactive inflammatory responses is 
due to the aberrant production of inflammatory mediators including C-X-C motif chemokine 
ligand 5 (CXCL5). The molecular mechanism underlying induction of CXCL5 by NTHi is 
unknown. Here we show that the NTHi up-regulates CXCL5 expression by activating IKKβ-
IκBα and p38 MAPK pathways via NF-κB nuclear translocation-dependent and -independent 
mechanism in middle ear epithelial cells. Current therapies for OM are ineffective due to the 
emergence of antibiotic-resistant NTHi strains and risk of side effects with prolonged use of 
immunosuppressant drugs. In this study, we show that curcumin, derived from Curcuma longa 
plant, long known for its medicinal properties, inhibited NTHi-induced CXCL5 expression in 
vitro and in vivo. Curcumin suppressed CXCL5 expression by direct inhibition of IKKβ 
phosphorylation, and inhibition of p38 MAPK via induction of negative regulator MKP-1. Thus, 
identification of curcumin as a potential therapeutic for treating OM is of particular translational 
significance due to the attractiveness of targeting overactive inflammation without significant 
adverse effects. 
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2.2 Introduction 
Otitis media (OM) is the most common childhood bacterial infection [1] with 700 million 
occurrences globally each year [2]. OM frequently leads to conductive hearing loss, affecting 
children during the crucial period of speech and language development [3]. The gram-negative 
bacillus Nontypeable Haemophilus influenzae (NTHi) represents the cause of approximately 
one-third episodes of OM. Current treatments for OM rely on the systemic use of antibiotics, 
which has led to the emergence of multi-drug resistant bacterial strains [4, 5]. Therefore, there is 
an urgent need for developing alternate therapeutic strategies for treating OM. 
OM is characterized by the presence of excess inflammation in the middle ear [1]. During 
infection, epithelial cells act as the first line of defense by secreting numerous pro-inflammatory 
mediators including chemokines. Chemokines mainly act by recruiting neutrophils to the site of 
infection. While the appropriate neutrophil response is critical for the removal of the invading 
pathogen, excess inflammation can lead to tissue damage and perpetuate inflammation leading to 
detrimental effects, as seen across several inflammatory pathologies including OM [6-9]. Thus, 
tight regulation of inflammation is necessary.  
CXCL5/ENA-78 (epithelial neutrophil-activating peptide 78) of the Glu-Leu-Arg (ELR) 
motif-containing C-X-C chemokine family is critical for recruiting neutrophils in response to 
bacterial infections [10]. Epithelial-cell derived CXCL5 is vital in polymorphonuclear leukocytes 
(PMN)-driven destructive inflammatory responses in Mycobacterium tuberculosis-induced 
pulmonary tuberculosis. Cxcl5-/- mice were found to be resistant to fatal tuberculosis [11]. The 
role of CXCL5 in neutrophil trafficking in lipopolysaccharide (LPS)-induced lung inflammation 
in mice has been reported [12]. A recent study demonstrated that LPS-induced deregulated 
CXCL5 expression resulted in exaggerated neutrophil-mediated inflammation in pulmonary 
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bronchiolar cells [13]. CXCL5 is also involved in angiogenesis, tumor growth, and metastasis 
[14], with CXCL5 overexpression leading to poor survival in cancer patients [15]. Affymetrix 
chip analysis on mouse genome revealed marked up-regulation of CXCL5 expression by NTHi 
in the middle ear of mouse [16]. Middle ear effusion samples from patients with acute and 
chronic OM have shown the presence of viable NTHi trapped within neutrophil extracellular 
traps, which continued to elicit inflammatory responses [17, 18]. Thus, these findings suggest 
that therapeutic strategies to control aberrant CXCL5 production are of utmost importance for 
modulating inflammation. 
Current anti-inflammatory therapies act via suppressing the positive signaling pathways 
involved in the production of inflammatory mediators.  However, prolonged use of these drugs 
could have severe side effects because these pathways are also involved in mediating 
physiological responses. Therefore, therapeutic strategies that increase the levels of endogenous 
negative regulators of inflammation while leaving the positive pathways intact are gaining 
prominence [19]. Despite the importance of CXCL5 in mediating inflammation, the molecular 
mechanisms underlying the up-regulation of CXCL5 production in OM remains largely 
unknown. Therefore, understanding the mechanism of NTHi-induced CXCL5 regulation in OM 
will help develop new therapies. 
 Curcumin, a yellow pigment, common spice derived from the rhizome of Curcuma longa 
plant was long-used for its medicinal properties [20]. Curcumin has been widely reported to have 
anti-inflammatory, anti-oxidant, anti-microbial, anti-diabetic, anti-carcinogenic anti-tumorigenic, 
anti-amyloidogenic effects. Due to its tolerability and non-toxicity at high doses, curcumin could 
be used for prolonged periods without any side effects [20]. Completed clinical trials revealed 
promising therapeutic effects of curcumin in patients with cancer, inflammatory bowel disease, 
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irritable bowel disease, rheumatoid arthritis, Alzheimer’s disease, and diabetes [21-27]. More 
clinical trials evaluating the efficacy of curcumin on a broad range of inflammatory conditions 
are currently underway. Despite its widely known potent anti-inflammatory properties, the effect 
of curcumin on NTHi-induced inflammatory responses, especially CXCL5 expression remains to 
be evaluated. 
 In the present study, we investigated the underlying molecular mechanism of NTHi-
induced CXCL5 expression. We show that NTHi up-regulates CXCL5 expression by activating 
IKKβ-IκBα and p38 MAPK pathways. Interestingly both pathways mediated CXCL5 expression 
in an NF-κB-nuclear translocation-dependent and -independent manner, respectively. Also, we 
show that curcumin suppresses NTHi-induced CXCL5 expression in middle ear epithelial cells. 
Curcumin suppressed CXCL5 expression by direct inhibition of IKKβ phosphorylation and 
inhibition of p38 MAPK via induction of negative regulator MKP-1. Thus, our study provides 
novel insights into the regulation of CXCL5 chemokine and identifies curcumin as a potential 
therapeutic for treating OM. 
2.3 Materials and Methods 
2.3.1 Reagents and antibodies 
IKKb inhibitor IV and MG-132 were purchased from EMD Millipore. CAPE, SB203580 
were purchased from Enzo Life Sciences. Curcumin was purchased from Sigma. Antibodies for 
p-IKKa/b (#2697), p-p38 (#9211), p38 (#9212), anti-rabbit HRP-linked antibody (#7074) and 
anti-mouse HRP-linked antibody (#7076) were purchased from Cell Signaling Technology. 
Antibodies for IKKa/b (sc-7607), p65 (sc-8008), MKP-1 (sc-370), a-tubulin (sc-69969), c-Myc 
(sc-40), anti-mouse FITC-conjugated antibody (sc-2010), anti-rabbit Rhodamine-conjugated 
antibody (sc-2091) were purchased from Santa Cruz Biotechnology.  
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2.3.2 Cell culture 
All media described below were supplemented with 10% fetal bovine serum and 
100U/ml penicillin and 100 µg/ml streptomycin (Gibco). Human middle ear epithelial cells 
(HMEECs) were maintained in DMEM (Cellgro) supplemented with BEGM SingleQuots 
(Lonza). Lung epithelial A549 cells were maintained in F-12K medium (Gibco). Human cervical 
epithelial HeLa cells were maintained in DMEM (Cellgro). Cells were cultured at 37 °C in a 
humidified 5% CO2 atmosphere. 
2.3.3 Bacterial strains and culture conditions 
  Clinical isolates of NTHi strains 12, 2627, 9274 were used for this study [28, 29]. NTHi 
was grown on chocolate agar plate in 5% CO2 atmosphere for 16 h, followed by overnight 
culture in brain heart infusion (BHI) broth supplemented with 3.5 µg/ml NAD and 10 µg/ml 
hemoglobin (BD Biosciences). Subsequently, bacteria were subcultured in 5 ml fresh BHI broth 
and the growth was monitored by measurement of optical density (OD). Log phase bacteria were 
harvested, washed and re-suspended in DMEM for in vitro experiments and isotonic saline for in 
vivo experiments. For all in vitro experiments the cells were stimulated with NTHi at a 
multiplicity of infection (MOI) of 50, with an exception for dose-dependent experiment. Cells 
were stimulated with NTHi for 5 h, or otherwise as indicated. For inhibition study, cells were 
pretreated with the respective inhibitor for 1 h prior to NTHi stimulation. For post-treatment 
studies cells were treated with curcumin 1 h after NTHi stimulation. 
2.3.4 Plasmids, transfection and luciferase assay 
The expression plasmids, for dominant negative (DN) forms of TLR2, TLR4, TRAF6, 
MyD88, IKKa (K44M), IKKb (K49A), p38a (fp38a (AF)), p38b (fp38b2 (AF)), trans dominant 
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IkBa (S32A/S36A), constitutively active form of IKKb (IKKb-CA, S176E/S180E), p65 have 
been described previously [31, 59]. NF-kB luciferase reporter vector (pGL4.32) was purchased 
from Promega. Myc-MKP-1 overexpression plasmid was subcloned from previously described 
pSG5 – MKP-1 plasmid [53]. MKP-1 sequence was amplified using the primers 5’-
GGTCTCGAGCGATGGTCATGGAAGTGG-3’ and 5’-
GGTGGATCCTCCGCAGCTGGGAGAGGT-3’ and inserted into the XhoI and BamHI sites of 
pcDNA3.1/mycHis(-) vector. All transient transfections were performed using TransIT-LT-2020 
transfection reagent (Mirus) according to the manufacturer’s protocol. Cells were assayed 48 h 
after transfection. Empty vector was transfected as a control. pSV-b-Galactosidase vector was 
used as a control for luciferase assay. Luciferase activity and b-Galactosidase activity was 
measured using Luciferase Assay System (Promega) and b-Galactosidase Enzyme Assay system 
(Promega). NF-kB luciferase activity was normalized with respect to b-Galactosidase activity. 
2.3.5 RNA-mediated interference 
Human siRNA (Control, D001810-10; IKKb, L003503-00; p65, L003533-00; TAK1, 
M003790-06-0005) were purchased from GE Health care. Cells were transfected with 20 nM 
siRNA using DharmaFECT-4 (Thermo Scientific) according to manufacturer’s protocol. Human 
pSUPER-shMKP-1 knockdown construct was previously described [60]. shMKP-1 was 
transfected using TransIT-LT-2020 transfection reagent (Mirus) according to manufacturer’s 
protocol. Cells were assayed 48 h after transfection. 
2.3.6 Real-time quantitative PCR (Q-PCR) analysis 
Total RNA was isolated with TRIzol reagent (Life Technologies) according to 
manufacturer’s protocol. Reverse transcription reaction was performed with 1µg RNA using 
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TaqMan reverse transcription reagents (Applied Biosystems) according to manufacturer’s 
protocol. Quantitative PCR was performed using Fast SYBR Green Master Mix. PCR reactions 
containing 2X universal master mix, 1 µL template cDNA, 500 nM primers in a final volume of 
12.5 µL, were amplified and quantified using StepOnePlus Real-Time PCR system (Applied 
Biosystems). Relative quantities of mRNAs were obtained using the comparative Ct method and 
were normalized to human Cyclophilin or mouse glyceraldehyde-3-phosphate (GAPDH); 
serving as an endogenous control. Human (h) and mouse (m) primer sequences are as follow: 
hCXCL5 5’-GTGGTAGCCTCCCTGAAGAAC-3’ and 5’-TCCTTGTTTCCACCGTCCAA-3’; 
hTAK1 5’-GCAACAGAGTGAATCTGGAC-3’ and 5’-CAGACATGTCAGCACTCATC-3’; 
mCXCL5 5’-GCTGGCATTTCTGTTGCTGTTC-3’and 5’-GGCAGCTTCAGCTAGATGCT-3’. 
hMKP-1, hCyclophilin and mGAPDH primer sequences were previously described [60].  
2.3.7 Enzyme-linked immunosorbent assay (ELISA) 
Cells were stimulated with NTHi for 12h. Culture media was harvested and centrifuged at 
12,000 x g for 10 min to precipitate cell debris. Culture supernatants were assayed using human 
ENA78/ CXCL5 ELISA kit (Sigma) according to manufacturer’s protocol. OD was measured 
using Benchmark Plus microplate spectrophotometer. A standard curve showing the relationship 
between concentration and OD was generated for CXCL5 protein standards. CXCL5 protein 
concentration in culture supernatants was determined by interpolating from the standard curve. 
2.3.8 Western Blot Analysis 
Following NTHi stimulation, whole cell extracts were recovered with lysis buffer 
containing 50 mM Tris-HCl (pH 7.4), 1% Nonidet P-40, 0.25% deoxycholate, 150 mM NaCl, 1 
mM EDTA, 1 mM NaF, supplemented with1 mM PMSF, 1 mM Na3VO4 and protease inhibitor 
cocktail). Cell extracts were incubated on ice for 30 min and centrifuged at 12,000 x g for 30 min 
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to precipitate cell debris. Supernatants were separated on 10% SDS-PAGE gel, transferred to 
polyvinylidene difluoride (PVDF) membrane. The membrane was blocked with blocking buffer 
(TBS containing 0.1% Tween 20 (TBS-T) and 5% nonfat dry milk). After 3 washes with TBS-T, 
the membrane was incubated overnight with primary antibodies at 1 : 1,000 − 1 : 2,000 dilutions 
in antibody dilution buffer (TBS-T containing 5% BSA) at 4 °C. After 3 washes with TBS-T, the 
membrane was incubated with corresponding secondary antibody at 1 : 5,000 dilution in 
blocking buffer for 1 h. After 3 washes with TBS-T, the proteins were visualized using 
Amersham ECL Prime Detection Reagent (GE Healthcare). Images have been cropped for 
presentation. Full-size images are presented in Supplementary Figs. 1−4. 
2.3.9 Mice and Animal Experiments 
C57BL/6 mice were purchased from Jackson Laboratories. Anesthetized mice were trans-
tympanically inoculated with NTHi at a concentration of 5 x 107  CFU per mouse. Saline was 
inoculated as control. For inhibition studies, mice were injected intraperitoneally (i.p) with 
curcumin (50 mg/kg) 1 h prior or 1 h after NTHi inoculation. For mRNA analysis, mice were 
sacrificed 6 h post-NTHi inoculation. Total RNA was extracted from the dissected mice middle 
ear. For PMN analysis, mice were sacrificed 9 h post-NTHi inoculation. Middle ear effusions 
from mice were harvested with 10µl saline (✕3). Following cytocentrifugation cells were stained 
with Diff-Quik stain kit (Siemens) according to manufacturer’s protocol. Images were recorded 
with light microscopy system (AxioVert 40 CFL, AxioCam MRC and AxioVision LE Image 
system, Carl Zeiss). All animal studies were carried out in accordance with the guidelines of, and 
were approved by, The Institutional Animal Care and Use Committee at Georgia State 
University. 
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2.3.10 Immunofluorescence staining 
HMEECs were grown on 18 mm round glass coverslips (VWR). Cells were fixed in 4% 
paraformaldehyde. Cells were then incubated with primary antibodies at 1 : 100 − 1 : 400 
dilutions. Primary antibody was detected with FITC or Rhodamine-conjugated secondary 
antibody. The coverslips were mounted onto glass slides using VECTASHIELD HardSet 
Antifade mounting Medium with DAPI (Vector). Images were recorded with fluorescence 
microscopy system (AxioVert 40 CFL, AxioCam MRC and AxioVision LE Image system, Carl 
Zeiss). 
2.3.11 Statistical analysis 
All experiments were repeated in at least three independent experiments. Data are shown 
as mean ± standard deviation (s.d.). The difference in means was assessed with unpaired 
student’s t-test for data with two conditions (k = 2), ANOVA (with Tukey’s post-hoc) for data 
with more than two conditions (k > 2), using SPSS 22 statistics software (IBM). *p < 0.05 was 
considered statistically significant. 
2.4 Results 
2.4.1 NTHi induces CXCL5 expression in middle ear epithelial cells in vitro and in vivo. 
Epithelial cells act as the first line of defense against injurious stimuli by mediating 
inflammatory responses. We sought to determine if NTHi induces CXCL5 expression in human 
middle ear epithelial cells (HMEECs). NTHi induced CXCL5 mRNA expression in a dose- (Fig. 
2.1A) and time-dependent (Fig. 2.1B) manner in HMEECs. NTHi induced up-regulation of 
CXCL5 protein expression in HMEECs as quantified by ELISA (Fig. 2.1C). Effect of NTHi on 
CXCL5 expression was also confirmed in human airway epithelial BEAS-2B cells, human lung 
epithelial A549 cells and human cervical epithelial HeLa cells, suggesting the generalizability of 
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this phenomenon to multiple epithelial cells (Fig. 2.1D). We further explored the generalizability 
of NTHi-induced CXCL5 expression by employing two additional commonly used clinical 
NTHi strains 2627 and 9274 known to cause OM [28, 29]. NTHi strains 2627 and 9274 also 
induced CXCL5 mRNA expression at levels comparable to that of NTHi strain 12 (used 
throughout the study) in HMEECs (Fig. 2.1E). Consistent with the in vitro findings, NTHi also 
induced up-regulation of CXCL5 mRNA in mouse middle ear (Fig. 2.1F). 
2.4.2 TLR2-MyD88-TRAF6-TAK1 signaling axis is required for NTHi-induced CXCL5 
expression. 
Toll-like receptors (TLRs) are cell surface receptors that play a critical role in mounting 
early innate immune responses against invading pathogens. TLRs recognize conserved motifs 
known as pathogen-associated microbial patterns (PAMPs), expressed on microbial pathogens 
and initiate signaling cascades leading to the production of pro-inflammatory mediators. To date, 
at least 11 human TLRs have been identified. Among them, TLR2 is known to recognize 
lipopolysaccharide (LPS), characteristic of Gram-negative bacteria. Based on our previous 
finding that TLR2 mediated NTHi-induced pro-inflammatory signaling cascades, we sought to 
determine its role in CXCL5 chemokine production. HMEECs were transfected with TLR 
dominant-negative mutants TLR2-DN and TLR4-DN.  Overexpression of TLR2-DN 
significantly decreased NTHi-induced CXCL5 mRNA expression, whereas TLR4-DN had no 
significant effect on CXCL5 expression (Fig. 2.2A). Next, we sought to determine the signaling 
molecules downstream of TLR2, involved in mediating CXCL5 expression. Following 
recognition of NTHi by TLR2, myeloid differentiation factor 88 (MyD88) adaptor protein is 
recruited to the receptor. MyD88 then recruits and activates IL-1 receptor-associated kinases 
(IRAKs), which further lead to the recruitment and activation of tumor-necrosis factor-receptor-
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associated factor 6 (TRAF6). IRAK-TRAF6 complex dissociates from the receptor bound 
complex and further interacts with transforming growth factor-b- activated kinase 1 (TAK1). 
Activation of TAK1 leads to initiation of further downstream signaling pathways, resulting in 
nuclear translocation of transcription factors, and in turn regulates the expression of pro-
inflammatory mediators. To determine the involvement of MyD88 and TRAF6 in CXCL5 
expression, HMEECs were transfected with dominant-negative mutants MyD88-DN and 
TRAF6-DN. Overexpression of MyD88-DN and TRAF6-DN significantly suppressed NTHi-
induced CXCL5 expression (Fig. 2.2B). Depletion of endogenous TAK1 with TAK1 siRNA also 
decreased CXCL5 mRNA expression (Fig. 2.2C). TAK1 siRNA knockdown efficiency was 
confirmed by Q-PCR. Therefore, these results suggest that TLR2-MyD88-TRAF6-TAK1 
signaling axis is required for NTHi-induced CXCL5 expression. 
2.4.3 Activation of IKKβ-IκBα signaling pathway is required for NTHi-induced CXCL5 
expression. 
Previous studies have shown that IKKb signaling axis is crucial for NTHi-induced 
inflammatory responses [30]. Therefore, we examined the role of IKKb in up-regulation of 
CXCL5. We first confirmed that NTHi activates IKKb in HMEECs. IKKα/b phosphorylation 
was observed at 15 minutes, followed by a peak at 30 minutes, and declined after that (Fig. 
2.3A). To determine if IKKb is required for NTHi-induced CXCL5 expression, we used multiple 
approaches. IKKb inhibitor significantly suppressed NTHi-induced CXCL5 mRNA expression 
in a dose-dependent manner (Fig. 2.3B). To identify the major IKK isoform involved in NTHi-
induced CXCL5 regulation, HMEECs were transfected with IKK dominant-negative (DN) 
mutants IKKα-DN and IKKb-DN.  Overexpression of IKKb-DN significantly decreased NTHi-
induced CXCL5 mRNA expression, whereas IKKα-DN had no significant effect (Fig. 2.3C). 
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Consistent with this result, depletion of endogenous IKKb with IKKb siRNA also decreased 
CXCL5 mRNA expression (Fig. 2.3D). IKKb siRNA knockdown efficiency was confirmed by 
Western blot. To further confirm that activated IKKb induces CXCL5 expression, HMEECs 
were transfected with constitutively active (CA) form IKKb-CA. Overexpression of IKKb-CA 
markedly induced CXCL5 expression in a dose-dependent manner (Fig. 2.3E). Phosphorylation 
and proteasomal degradation of IkBa, by IKKb, are required for signal transduction [31]. 
Overexpression of a trans-dominant mutant form of IkBa (IkBa-DN) suppressed NTHi-induced 
CXCL5 expression (Fig. 2.3F). To further confirm that IkBa degradation is essential for NTHi-
induced CXCL5 up-regulation, we used MG-132 proteasome inhibitor. MG-132 significantly 
suppressed NTHi-induced CXCL5 mRNA expression in a dose-dependent manner (Fig. 2.3G). 
Thus, these results suggest that IKKb-IkBa signaling pathway is required for CXCL5 induction 
by NTHi. 
2.4.4 Activation of p38 signaling is required for NTHi-induced CXCL5 expression. 
NTHi has been shown to mediate inflammatory responses via activation of p38 MAPK 
signaling axis in addition to activation of IKKb-IkBa pathway [31]. Therefore, we examined the 
role of p38 in up-regulation of CXCL5.  We first confirmed that NTHi activates p38 MAPK in 
HMEECs. p38 phosphorylation was observed at 15 minutes, followed by a peak at 30 minutes, 
and declined after that (Fig. 2.3H). To determine if p38 MAPK activation is essential for NTHi-
induced CXCL5 expression, multiple approaches were used. SB203580, a specific inhibitor of 
p38 activation, significantly suppressed NTHi-induced CXCL5 mRNA expression in a dose-
dependent manner (Fig. 2.3I). To identify the major p38 isoform involved in NTHi-induced 
CXCL5 regulation, HMEECs were transfected with p38 DN mutants p38a-DN and p38b-DN. 
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Over-expression of either or both p38 a, b DN forms significantly decreased NTHi-induced 
CXCL5 expression (Fig. 2.3J), consistent with SB203580 data. Together, these data suggest that 
p38 pathway is required for induction of CXCL5. 
2.4.5 IKKb-IkBa and p38 signaling axes mediate CXCL5 induction via p65 nuclear 
translocation-dependent and -independent mechanism, respectively. 
Next, we sought to determine how IKKb-IkBa and p38 signaling pathways induce 
CXCL5 expression. Co-treatment with IKKb inhibitor and SB203580 synergistically suppressed 
CXCL5 expression at mRNA (Fig. 2.4A) and protein (Fig. 2.4B) levels. As NF-kB is a known 
major transcription factor for pro-inflammatory mediators [32], we investigated its involvement 
in NTHi-induced CXCL5 expression. Nuclear translocation of NF-kB is critical for its activity 
[32]. NTHi induces nuclear translocation of p65, the major subunit of NF-kB complex [31]. To 
determine that p65 nuclear translocation and activation is required for NTHi-induced CXCL5 
expression, we used multiple approaches. Pretreatment with caffeic acid phenyl ester (CAPE), a 
specific inhibitor of NF-kB nuclear translocation (independent of IkBa degradation), completely 
abrogated NTHi-induced CXCL5 expression (Fig. 2.4C). Pretreatment with CAPE markedly 
diminished NTHi-induced NF-kB promoter-driven luciferase activity (Fig. 2.4D). Depletion of 
endogenous p65, with p65 siRNA, decreased CXCL5 mRNA expression (Fig. 2.4E).  p65 siRNA 
knockdown efficiency was confirmed by Western blot. Overexpression of p65 further enhanced 
NTHi-induced CXCL5 expression (Fig. 2.4F). Therefore, these results suggest that NTHi 
induces CXCL5 transcription via activation of NF-kB, specifically by p65 subunit. 
To determine whether p38 MAPK induces CXCL5 expression via p65, HMEECs 
transfected with p65 were pre-treated with SB203580, prior to NTHi stimulation. SB203580 
decreased CXCL5 expression in p65-transfected cells (Fig. 2.4G). We further confirmed the 
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requirement of p38 for NF-kB activation by multiple approaches. Pre-treatment with SB203580 
markedly decreased NTHi-induced NF-kB promoter-driven luciferase activity (Fig. 2.4H). 
Consistent with this result, over-expression of either or both p38a and p38b DN forms decreased 
NTHi-induced NF-kB promoter activity (Fig. 2.4I). These results suggest that p38 MAPK also 
mediates NTHi-induced CXCL5 expression in a p65 dependent mechanism. 
Since nuclear translocation of p65 is imperative for NF-kB-driven gene expression [32], 
we determined if p38 up-regulates CXCL5 expression via facilitating nuclear translocation of 
p65 by immunofluorescence staining. CAPE markedly inhibited nuclear translocation of p65, 
whereas SB203580 did not show any significant effect (Fig. 2.4J). Taken together these results 
suggest that p38 mediates CXCL5 expression via a mechanism independent of the nuclear 
translocation of p65. Therefore, these results suggest that IKKβ and p38 signaling pathways 
mediate NTHi-induced CXCL5 up-regulation via activation of p65 in a p65-nuclear 
translocation-dependent and -independent mechanism, respectively.  
2.4.6 Curcumin suppresses NTHi-induced CXCL5 expression in vitro and in vivo. 
Having identified the molecular mechanisms underlying NTHi-induced up-regulation of 
CXCL5, we next sought to explore the translational significance of these findings. Because 
curcumin, a promising anti-inflammatory agent, has previously been shown to inhibit NF-kB 
[33, 34], we first determined if curcumin inhibits NTHi-induced up-regulation of CXCL5. 
Curcumin pre-treatment inhibited CXCL5 mRNA expression in a dose-dependent manner (Fig. 
2.5A). Curcumin's inhibitory effect on CXCL5 protein levels was also confirmed (Fig. 2.5B). 
Additionally, the inhibitory effect of curcumin on CXCL5 mRNA expression was also observed 
in HMEECs stimulated with other common clinical NTHi strains 2627 and 9274 (Fig. 2.5C), 
thereby suggesting the generalizability to more OM-causing NTHi strains. Consistent with in 
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vitro findings, curcumin pre-treatment inhibited CXCL5 mRNA expression in the middle ear of 
mice inoculated with NTHi (Fig. 2.5D). These data suggest that curcumin inhibits NTHi-induced 
CXCL5 expression in middle ear epithelial cells in vitro and in vivo. 
Next, we sought to determine the therapeutic relevance of the inhibitory effect of 
curcumin in NTHi-induced OM model. Thus, we evaluated the effect of administering curcumin 
post-NTHi infection that resembles a clinically relevant setting. Administering curcumin post-
NTHi infection significantly suppressed NTHi-induced CXCL5 mRNA expression in vitro (Fig. 
2.5E) and in vivo (Fig. 2.5F). Curcumin suppressed CXCL5 expression to the same extent under 
both pre-NTHi and post-NTHi infection conditions. Since CXCL5 is a neutrophil 
chemoattractant, we further evaluated the effect of curcumin on PMN recruitment in response to 
NTHi infection in a mouse model of OM. Consistent with the above results curcumin (pre-NTHi 
and post-NTHi infection) inhibited PMN infiltration as assessed by PMN staining of middle ear 
effusion from mice (Fig. 2.5G). Thus, these data suggest that curcumin is a potential therapeutic 
for treating NTHi-induced inflammation as seen in OM. 
2.4.7 Curcumin suppresses NTHi-induced CXCL5 expression via inhibition of IKKb and 
p38 pathways. 
Next, we sought to determine the mechanism by which curcumin inhibits CXCL5 
expression. Since activation of IKKb-IkBa and p38 signaling pathways has been shown to be 
involved in NTHi-induced CXCL5 expression, we assessed the effect of curcumin on these 
pathways. Curcumin abrogated NTHi-induced IKKa/b phosphorylation (Fig. 2.6A). Moreover, 
curcumin inhibited IKKb-CA-induced CXCL5 expression (Fig. 2.6B). Curcumin reduced NTHi-
induced p38 phosphorylation (Fig. 2.6C). We also confirmed the inhibitory effect of curcumin on 
NTHi-induced p38 phosphorylation by immunofluorescence staining (Fig. 2.6D). Next, we 
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determined the effect of curcumin on p65 nuclear translocation and NF-kB-driven luciferase 
promoter activity. Consistent with the above findings, curcumin suppressed NTHi-induced p65 
nuclear translocation (Fig. 2.6E) and NF-kB luciferase activity (Fig. 2.6F). Thus, these data 
suggest that curcumin inhibits NTHi-induced CXCL5 expression via inhibition of both IKKb-
IkBa and p38 signaling pathways. 
2.4.8 Curcumin suppresses CXCL5 expression via up-regulation of negative regulator MKP-
1. 
MKP-1, a member of a class of dual specificity phosphatases collectively termed MAPK 
phosphatases, has been shown to be a key negative regulator of inflammatory responses via 
dephosphorylation and inactivation of MAPKs, including p38 [35, 36]. Since we identified the 
requirement of p38 MAPK activation in NTHi-induced CXCL5 expression, we determined the 
role of MKP-1 in CXCL5 regulation. Overexpression of MKP-1 suppressed NTHi-induced 
CXCL5 expression (Fig. 2.7A). Depletion of endogenous MKP-1 with MKP-1 shRNA enhanced 
CXCL5 mRNA expression (Fig. 2.7B). MKP-1 shRNA knockdown efficiency was confirmed by 
Q-PCR. These data suggest that MKP-1 is a negative regulator of NTHi-induced CXCL5 
induction.  
To further determine if MKP-1 acts as a negative regulator of CXCL5 induction via 
inactivation of p38, we evaluated the effect of MKP-1 on p38 phosphorylation. Overexpression 
of MKP-1 reduced NTHi-induced p38 phosphorylation (Fig. 2.7C). In contrast, depletion of 
MKP-1 enhanced p38 phosphorylation (Fig. 2.7D). These data suggest that MKP-1 negatively 
regulates NTHi-induced CXCL5 expression by targeting p38 MAPK. 
Since curcumin and MKP-1 were identified to suppress activation of p38, we sought to 
determine if curcumin up-regulates MKP-1 expression. Curcumin markedly enhanced NTHi-
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induced MKP-1 expression at mRNA (Fig. 2.7E) and protein (Fig. 2.7F) levels. These data 
suggest the curcumin increases NTHi-induced expression of negative regulator MKP-1. 
Having shown that curcumin inhibits NTHi-induced CXCL5 via inhibition of p38 and 
up-regulation of MKP-1 expression, we sought to determine if the inhibitory effect of curcumin 
on p38 is dependent on the up-regulation of MKP-1. Depletion of MKP-1 with shMKP-1 
rendered curcumin treatment ineffective in inhibiting NTHi-induced CXCL5 expression (Fig. 
2.7G). Additionally, curcumin no longer suppressed NTHi-induced p38 phosphorylation in the 
absence of MKP-1 (Fig. 2.7H). These data suggest that curcumin inhibits NTHi-induced 
activation of p38 via up-regulating MKP-1. Thus, our results suggest that curcumin inhibits 
NTHi-induced CXCL5 expression via MKP-1-dependent inhibition of p38 MAPK. 
2.5 Discussion 
Inflammatory responses are essential for the containment, removal of the invading 
pathogens and recovery of the host. However, excess inflammation can be detrimental to the host 
as seen in OM [6-9, 37, 38]. Therefore, tight regulation of the intensity and duration of 
inflammatory responses is necessary. In the present study, we show that curcumin inhibits 
CXCL5 chemokine up-regulation in NTHi-induced OM model, in vitro and in vivo. We found 
that NTHi up-regulated CXCL5 expression by activating IKKβ-IκBα and p38 MAPK pathways 
via NF-κB nuclear translocation-dependent and -independent mechanism. Curcumin not only 
inhibited the positive IKKβ pathway but also up-regulated the expression of MKP-1, a key 
negative regulator of p38 MAPK, thereby suppressing CXCL5 expression by dual action. Thus, 
the current study provides novel insights into the molecular mechanism underlying the tight 
regulation of neutrophil attractant chemokine CXCL5 in the pathogenesis of NTHi-induced OM 
and also demonstrates the potential of curcumin as a novel therapeutic for treating OM (Fig. 2.8). 
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NF-kB was found to be the major transcription factor regulating NTHi-induced CXCL5 
expression. In our study, both IKKb-IkBa and p38 MAPK pathways were found to act via p65 
subunit to regulate NF-kB transcriptional activity, albeit through different mechanisms to induce 
CXCL5 expression.  Under resting conditions NF-kB is present in the cytoplasm bound to IkBa. 
Upon activation of upstream signaling pathways, NF-kB dissociates from IkBa and translocates 
to the nucleus to regulate gene expression. CAPE, an inhibitor of NF-kB nuclear translocation, 
inhibited p65 nuclear translocation and suppressed NF-kB transcriptional activity that in turn 
suppressed CXCL5 expression. Interestingly p38 MAPK inhibitor SB203580 failed to inhibit 
p65 nuclear translocation but suppressed NF-kB transcriptional activity and CXCL5 expression. 
These findings suggest that p38 MAPK regulates NF-kB transcriptional activity itself but not 
p65 nuclear translocation. Previous studies have reported that post-translational modifications 
such as phosphorylation and acetylation of p65 are critical for promoting its DNA binding and 
interaction with transcriptional machinery to regulate gene expression. p38 MAPK was found to 
regulate the acetylation status of p65 but not its phosphorylation. In response to activating 
stimuli, p38 was found to phosphorylate the transcriptional coactivator p300 (a histone 
acetyltransferase). Phosphorylated p300 binds to and acetylates K310 residue on p65. 
Acetylation of K310 was shown to enhance p65 transcriptional activity [39]. Therefore it likely 
that p38 MAPK mediates NTHi-induced CXCL5 expression in a similar manner by increasing 
NF-κB transcriptional activity, independent of p65 nuclear translocation. 
OM, a leading cause of conductive hearing loss in children, is caused by NTHi [1]. OM is 
characterized by the presence of excessive inflammation in the middle ear [3, 40]. Current 
therapies for OM involve the use of analgesics and antipyretics for symptomatic treatment [41]. 
Though these medications are effective during certain stages of the disease, prolonged usage 
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poses the risk of serious side effects due to unknown “off-targets” and weakened immune 
system. Decongestants, antihistamines, and corticosteroids have not been effective in treating 
OM [42]. Prophylactic use of antibiotics has rendered over 80% of the NTHi strains drug-
resistant [4, 5]. Also, development of vaccines against NTHi remains a challenge due to the high 
genetic diversity of NTHi strains and high antigenic variability of surface-exposed antigens [43, 
44]. Thus, there is an urgent need for developing alternative therapeutics for OM with increased 
efficiency and safety. Therefore, identifying the underlying molecular mechanisms leading to up-
regulation of inflammation is critical for the development of novel therapeutic strategies with 
increased specificity and reduced side effects. Interestingly, in the current study we provide 
evidence that curcumin inhibits NTHi-induced CXCL5 chemokine expression in middle ear 
epithelial cells. Interestingly, both pre-infection and post-infection treatment with curcumin not 
only inhibited NTHi-induced CXCL5 up-regulation but also suppressed PMN infiltration into the 
middle ear in a mouse model of OM. Curcumin treatment’s efficacy in inhibiting CXCL5 
expression and PMN recruitment post-NTHi infection is of particular clinical significance.  
Recently chemokines and chemokine receptors are increasingly considered as targets for 
developing new drugs to control inflammation [45]. Our finding that curcumin suppresses NTHi-
induced CXCL5 chemokine expression is of particular relevance in the current scheme of 
identifying chemokine-drug combinations to treat inflammation. Thus, curcumin could be 
repurposed as a new therapeutic for treating OM. 
Curcumin is a nutraceutical that has been in use in South Asian countries for many 
centuries owing to its medicinal properties [20]. Curcumin can interact with a myriad of 
signaling molecules including transcription factors, protein kinases, growth factors, receptors, 
adhesion molecules, pro-inflammatory cytokines [46], thus explaining it pleiotropic therapeutic 
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potential against a wide range of diseases. Curcumin does not present a dose-limiting toxicity, 
making it suitable for prolonged usage. Completed clinical trials reported usage of curcumin 
dosage ranging from 0.045 to 8 g/day. Currently, 38 clinical trials evaluating the efficacy of 
curcumin at a dosage ranging from 0.18 to 8 g/day for treating pathologies such as Alzheimer’s 
disease, diabetes, kidney disease, Crohn’s disease, cancer are underway [47]. United States Food 
and Drug Administration classified curcumin as GRAS (generally recognized as safe), 
warranting its use as a supplement. In the current study, we identified a novel role of curcumin in 
suppressing CXCL5 chemokine production. Co-administration of curcumin along with piperine, 
docetaxel, soy isoflavones, bioperine, lactoferrin, mesalamine in clinical trials [48-52], suggest 
the possibility of customizing curcumin-based therapies to maximize its therapeutic efficiency. 
Since bioavailability of curcumin is a challenge [47], further studies combining the use of 
adjuvants, lipids, nanoparticles are needed to elucidate further the potency of curcumin in 
treating OM. 
Another relevant finding of biological significance in the current study is the dual acting 
mechanism of curcumin in inhibiting CXCL5 expression. Curcumin inhibited NTHi-induced 
IKKb phosphorylation, thereby suppressing CXCL5 up-regulation. Moreover, we found that 
curcumin also inhibits NTHi-induced CXCL5 expression via MKP-1-dependent suppression of 
p38 MAPK. In the absence of MKP-1, curcumin failed to suppress CXCL5 expression. Due to 
the importance of p38 in maintaining homeostasis, up-regulation of negative regulator MKP-1 by 
curcumin could play an important role in controlling the over-active immune responses with 
minimal side effects. This finding is of particular translational significance due to the 
attractiveness of targeting overactive inflammation via induction of negative-regulators [19].  
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We previously demonstrated that dexamethasone glucocorticoid inhibits p38 MAPK via 
up-regulation of MKP-1 [53]. Glucocorticoids owing to their potent immunosuppressive and 
anti-inflammatory effects have been in use for treating a gamut of diseases such as asthma, 
allergies, skin disorders, multiple sclerosis, immune disorders and cancer. However, prolonged 
usage has been reported to cause severe, sometimes irreversible side effects such as osteoporosis, 
endocrine and metabolic disorders, behavioral and cognitive changes, gastrointestinal tract 
complications, uveitis and weakened immune system [54]. Numerous studies over the past years 
have demonstrated curcumin’s efficacy in resolving pathologies was similar to that of 
dexamethasone [55, 56]. No evidence of side effects with low to moderate consumption of 
curcumin exists. With a higher curcumin dosage 12 g/day, mild symptoms such as diarrhea, low 
blood sugar, abdominal pain, and indigestion have been reported [47]. Additionally, curcumin 
has been reported to aid in overcoming the side effects of glucocorticoid usage [57]. Curcumin is 
also effective against oxidative stress, characteristic of many inflammatory conditions. Curcumin 
supplementation could be an effective disease preventive strategy due to its immunomodulatory 
activity [58]. Thus, curcumin fits the bill for an alternative therapeutic with minimal side effects.  
 In conclusion, our study demonstrates for the first time that curcumin is a potent inhibitor 
of CXCL5 chemokine, which could, in turn, suppress inflammation. Further studies promoting 
curcumin bioavailability may provide means to develop therapies to modulate inflammation 
more stringently without adverse effects. Development of drug delivery systems in the form of a 
topical ointment and ear drops could be of clinical significance in treating OM. The findings of 
this study may have applications in a broader context to other pathologies including chronic 
obstructive pulmonary disease, tuberculosis, cancer and Alzheimer’s disease. 
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Figure 2.1 NTHi up-regulates CXCL5 expression in middle ear epithelial cells in vitro and in 
vivo 
(A) HMEECs were stimulated with NTHi (MOI of 25, 50 or 250) for 5 h, and CXCL5 mRNA expression was 
measured by Q-PCR. (B) HMEECs were stimulated with NTHi (MOI of 50) for 1, 3 or 5 h, and CXCL5 mRNA 
expression was measured by Q-PCR. (C) HMEECs were stimulated with NTHi for 12 h, and CXCL5 protein levels 
in cell culture supernatants was measured by ELISA. (D) Airway epithelial BEAS-2B cells, lung epithelial A549 
cells and cervical epithelial HeLa cells were stimulated with NTHi for 5 h, and CXCL5 mRNA expression was 
measured by Q-PCR. (E) HMEECs were stimulated with NTHi strains 12, 2627 or 9274 for 5 h, and CXCL5 
mRNA expression was measured by Q-PCR.  (F) Mice were trans-tympanically inoculated with NTHi (6 x 107 
CFU) for 6 h, and CXCL5 mRNA expression in middle ear was measured by Q-PCR. Data are mean ± s.d. (n=3). A, 
B, E; *p < 0.05, ANOVA (Tukey’s post-hoc). C, D, F; *p < 0.05, t-test. Data are representative of three or more 
independent experiments. 
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Figure 2.2 TLR2-MyD88-TRAF6-TAK1 signaling axis is required for NTHi-induced CXCL5 
expression  
(A-B) HMEECs were transfected with Mock, TLR2-DN, TLR4-DN, MyD88-DN or TRAF6-DN plasmid. Cells 
were stimulated with NTHi for 5 h, and CXCL5 mRNA expression was measured. (C) HMEECs were transfected 
with control siRNA or TAK1 siRNA. Cells were stimulated with NTHi for 5 h, and CXCL5 mRNA expression was 
measured. Knockdown of TAK1 by siRNA was confirmed by Q-PCR. Data are mean ± s.d. (n=3). A, B; *p < 0.05, 
ANOVA (Tukey’s post-hoc). C; *p < 0.05, t-test. Data are representative of three or more independent experiments. 
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Figure 2.3  Activation of IKKb-IkBa and p38 signaling pathways are required for NTHi-induced 
CXCL5 expression 
(A) HMEECs were stimulated with NTHi for various time intervals as indicated in the figure. Phospho-IKKa/b, 
total IKKa/b protein levels were visualized by western blot. (B) HMEECs were pre-treated with IKKb inhibitor 
(0.25, 0.5 or 1.0 µM) for 1 h, followed by stimulation with NTHi for 5 h, and CXCL5 mRNA expression was 
measured. (C) HMEECs were transfected with Mock, IKKa-DN or IKKb-DN plasmid. Cells were stimulated with 
NTHi for 5 h, and CXCL5 mRNA expression was measured. (D) HMEECs were transfected with control siRNA or 
IKKb siRNA. Cells were stimulated with NTHi for 5 h, and CXCL5 mRNA expression was measured. Knockdown 
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of IKKb protein by siRNA was confirmed by western blot. (E) HMEECs were transfected with Mock, IKKb - CA 
(0.25, 0.5 or 1 µg) plasmid. CXCL5 mRNA expression was measured. (F) HMEECs were transfected with Mock or 
IkBa (S32A/S36A) plasmid. Cells were stimulated with NTHi for 5 h, and CXCL5 mRNA expression was 
measured. (G) HMEECs were pre-treated with MG-132 (5, 10 or 20 µM) for 1 h, followed by stimulation with 
NTHi for 5 h, and CXCL5 mRNA expression was measured. (H) HMEECs were stimulated with NTHi for various 
time intervals as indicated in the figure. Phospho-p38, total p38 protein levels were visualized by western blot 
analysis. (I) HMEECs were pre-treated with SB203580 (5, 10 or 20 µM) for 1 h, followed by stimulation with NTHi 
for 5 h, and CXCL5 mRNA expression was measured. (J) HMEECs were transfected with Mock, p38a - DN, p38b 
- DN or both (p38a - DN and p38b - DN) plasmids. Cells were stimulated with NTHi for 5 h, and CXCL5 mRNA 
expression was measured. Data are mean ± s.d. (n=3). B, C, E, G, I, J; *p < 0.05, ANOVA (Tukey’s post-hoc). D, 
F; *p < 0.05, t-test. n.s., not significant. Data are representative of three or more independent experiments. 
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Figure 2.4 IKKb-IkBa and p38 signaling axes mediate CXCL5 induction via p65 nuclear 
translocation–dependent and –independent mechanism, respectively 
(A-B) HMEECs were treated with IKKb inhibitor (0.5 µM), SB203580 (10 µM) or both for 1 h, followed by 
stimulation with NTHi for (a) 5 h, and CXCL5 mRNA expression was measured, (b) 12 h, and CXCL5 protein 
levels in cell culture supernatants was measured by ELISA. (C) HMEECs were pre-treated with CAPE (5, 10 or 25 
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µg/ml) for 1 h, followed by stimulation with NTHi for 5 h, and CXCL5 mRNA expression was measured. (D) 
HMEECs were transfected with NF-kB luciferase vector. Cells were pre-treated with CAPE (25 µg/ml) for 1 h, 
followed by NTHi stimulation for 5h. NF-kB promoter activity was measured by luciferase assay. (E) HMEECs 
were transfected with control siRNA or p65 siRNA. Cells were stimulated with NTHi for 5 h, and CXCL5 mRNA 
expression was measured. Knockdown of p65 protein by siRNA was confirmed by western blot. (F-G) HMEECs 
were transfected with Mock or p65. Cells were (F) stimulated with NTHi for 5 h, (G) pre-treated with SB203580 (20 
µM) for 1 h, followed by stimulation with NTHi for 5 h; and CXCL5 mRNA expression was measured. (H-I) 
HMEECs were transfected with (H) NF-kB luciferase vector alone, (I) NF-kB luciferase vector and Mock, p38a - 
DN, p38b - DN or both (p38a - DN and p38b - DN) plasmids. Cells were (H) pre-treated with SB203580 (20 µM) 
for 1 h and (H,I) stimulated with NTHi for 5 h. NF-kB promoter activity was measured by luciferase assay. (J) 
HMEECs were pre-treated with CAPE (25 µg/ml) or SB203580 (20 µM) for 1 h, followed by NTHi stimulation for 
1 h. p65 translocation was visualized by immunofluorescence by FITC staining. DAPI, nuclear stain. Magnification: 
400✕. Data are mean ± s.d. (n=3). A-C, F, G, I; *p < 0.05, ANOVA (Tukey’s post-hoc). D, E, H; *p < 0.05, t-test. 
Data are representative of three or more independent experiments. 
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Figure 2.5 Curcumin suppresses NTHi-induced CXCL5 expression in vitro and in vivo 
(A) HMEECs were pre-treated with curcumin (10, 20 or 50 µM) for 1 h, followed by stimulation with NTHi for 5 h, 
and CXCL5 mRNA expression was measured. (B) HMEECs were pre-treated with curcumin (20 µM) for 1 h, 
followed by stimulation with NTHi for 12 h, and CXCL5 protein levels in cell culture supernatants was measured by 
ELISA. (C) HMEECs were pre-treated with curcumin (20 µM) for 1 h, followed by stimulation with NTHi strains 
12, 2627 or 9274 for 5 h, and CXCL5 mRNA expression was measured. (D) Mice were pretreated with curcumin 
(50 mg/kg) (i.p) for 1 h, followed by trans-tympanic inoculation with NTHi (5 x 107 CFU) for 6 h, CXCL5 mRNA 
expression in dissected middle ear was measured. (E) HMEECs were pre-treated with curcumin (20 µM) 1 h prior 
NTHi stimulation or post-treated with curcumin (20 µM) 1 h after NTHi stimulation. 5 h after NTHi stimulation 
CXCL5 mRNA expression was measured. (F) Mice were pre-treated with curcumin (50 mg/kg) (i.p) for 1 h, 
followed by trans-tympanic inoculation with NTHi or post-treated with curcumin (50 mg/kg) (i.p) 1 h after NTHi 
inoculation. 6 h after NTHi inoculation CXCL5 mRNA expression in dissected middle ear was measured. (G) Mice 
were pre-treated with curcumin (50 mg/kg) (i.p) for 1 h, followed by trans-tympanic inoculation with NTHi or post-
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treated with curcumin (50 mg/kg) (i.p) 1 h after NTHi inoculation. Middle ear effusion was harvested 9 h after NTHi 
inoculation. Following cytocentrifugation, cells were stained with Diff-Quik staining kit. n.d., not detected. 
Magnification: 400✕. PMN cell count in middle ear effusion was determined using a hemocytometer under the 
microscope. n.d., not detected. Data are mean ± s.d. (n=3). A, E-G; *p < 0.05, ANOVA (Tukey’s post-hoc). B-D; 
*p < 0.05, t-test. n.s., not significant. Data are representative of three or more independent experiments. 
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Figure 2.6 Curcumin suppresses NTHi-induced CXCL5 expression via inhibition of IKKb and 
p38 pathways 
(A) HMEECs were treated with curcumin (20 µM) for 1 h, followed by stimulation with NTHi for various time 
intervals as indicated in the figure. Phospho-IKKb, total IKKb protein levels were visualized by western blot. (B) 
HMEECs were transfected with Mock or IKKb - CA plasmid. Cells were treated with curcumin (20 µM) for 1 h, 
and CXCL5 mRNA expression was measured. (C) HMEECs were treated with curcumin (20 µM) for 1 h, followed 
by stimulation with NTHi for various time intervals as indicated in the figure. Phospho-p38, total p38 protein levels 
were visualized by western blot. (D-E) HMEECs were pre-treated with curcumin (20 µM) for 1 h, followed by 
NTHi stimulation for (D) 30 min, (E) 1 h. (D) Phospho-p38, total p38 protein levels (Rhodamine stain), (E) p65 
translocation (FITC stain) was visualized by immunofluorescence. DAPI, nuclear stain. Magnification: 400✕. (F) 
HMEECs were transfected with NF-kB luciferase vector. Cells were pre-treated with curcumin (20 µM) for 1 h, 
followed by stimulated with NTHi for 5 h. NF-kB promoter activity was measured by luciferase assay.  Data are 
mean ± s.d. (n=3). B, F; *p < 0.05, t-test. Data are representative of three or more independent experiments. 
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Figure 2.7 Curcumin suppresses NTHi-induced CXCL5 expression via up-regulation of negative 
regulator MKP-1 
(A-B) HMEECs were transfected with (A) Mock or myc-MKP-1, (B) Mock or MKP-1 shRNA. Cells were 
stimulated with NTHi for 5 h, and CXCL5 mRNA expression was measured. Knockdown of MKP-1 protein by 
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shRNA was confirmed by Q-PCR. (C, D) HMEECs were transfected with (C) Mock or myc-MKP-1 plasmid, (D) 
Mock or shMKP-1 shRNA. Cells were stimulated with NTHi for times indicated. Phospho-p38, total p38, MKP-1 
protein levels were visualized by western blot. (E) HMEECs were pre-treated with curcumin (20 µM) for 1 h, 
followed by stimulation with NTHi for 1 h, and MKP-1 mRNA expression was measured. (F) HMEECs were pre-
treated with curcumin (20 µM) for 1 h, followed by stimulation with NTHi for various time intervals as indicated in 
the figure. MKP-1 and a-tubulin protein levels were visualized by western blot analysis. (G) HMEECs were 
transfected with Mock or MKP-1 shRNA. Cells were pre-treated with curcumin (20 µM) for 1 h, followed by NTHi 
stimulation for 5 h, and CXCL5 mRNA expression was measured. (H) HMEECs were transfected with Mock or 
MKP-1 shRNA. Cells were pre-treated with curcumin (20 µM) for 1 h, followed by NTHi stimulation for 30 min. 
Phospho-p38, total p38 protein levels were visualized by western blot. Data are mean ± s.d. (n=3). A, B, E; *p < 
0.05, t-test. G; *p < 0.05, ANOVA (Tukey’s post-hoc). n.s., not significant. Data are representative of three or more 
independent experiments. 
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Figure 2.8 Schematic representation of NTHi-induced CXCL5 expression and curcumin-
mediated suppression of CXCL5.  
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3 CURCUMIN INHIBITS NTHI-INDUCED MUC5AC MUCIN OVERPRODUCTION 
IN OTITIS MEDIA VIA UP-REGULATION OF MAPK PHOSPHATASE MKP-1 
 
Anuhya S Konduru, Byung-Cheol Lee, Jian-Dong Li* 
Under review for publication 
 
3.1 Abstract 
Otitis media (OM) characterized by the presence of mucus overproduction and excess 
inflammation in the middle ear is the most common childhood infection. Nontypeable 
Haemophilus influenzae (NTHi) pathogen is responsible for approximately one-third episodes of 
bacteria-caused OM. Current treatments for bacterial OM rely on the systemic use of antibiotics, 
which often leads to the emergence of multi-drug resistant bacterial strains. Therefore, there is an 
immediate need for developing alternative therapies strategies for controlling mucus 
overproduction in OM. MUC5AC mucin has been shown to play a critical role in the 
pathogenesis of OM. Here we show that curcumin derived from Curcuma longa plant is a potent 
inhibitor of NTHi-induced MUC5AC mucin expression in middle ear epithelial cells. Curcumin 
inhibited MUC5AC expression by suppressing activation of p38 MAPK by up-regulating MAPK 
phosphatase MKP-1. Thus, our study identified curcumin as a potential therapeutic for inhibiting 
mucin overproduction in OM by up-regulating MKP-1 a known negative regulator of 
inflammation.  
 
 
Keywords: Nontypeable Haemophilus influenzae, mucin, MUC5AC, otitis media, curcumin 
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3.2 Introduction 
Mucin glycoproteins are a major component of mucus secretions in the middle ear, 
trachea, digestive and reproductive tracts. Mucus production represents a protective innate 
defense mechanism to protect and lubricate the epithelium and trap invading pathogens for 
removal by the mucociliary clearance system [1]. However, in chronic infections, excess mucin 
impairs the mucociliary clearance system, resulting in mucus accumulation and poor function of 
the mucus-lined epithelial tracts. Of the ~24 mucin genes identified till date MUC5AC mucin 
has been shown to play a critical role in the pathogenesis of upper respiratory tract infections 
including otitis media (OM). OM is characteristic of the presence of mucus overproduction and 
excess inflammation in the middle ear [2, 3]. In patients with OM, increased mucus effusion into 
the ear’s tympanic cavity impairs the movement of the eardrum and middle ear bones and leads 
to hearing problems. A higher concentration of mucin in the middle ear effusion has been shown 
to correlate with the extent of hearing impairment [4, 5]. While mucin up-regulation is an 
important innate defense response of the host to infections in the middle ear, excess mucin can 
lead to impaired mucociliary clearance and conductive hearing loss [2]. Therefore, mucin 
expression must be tightly controlled.  
Nontypeable Haemophilus influenzae (NTHi) represents the cause of approximately one-
third episodes of OM. Current treatments for bacterial OM rely on the systemic use of 
antibiotics, which often leads to the emergence of multi-drug resistant bacterial strains [6, 7]. 
Development of NTHi vaccine remains a challenge due to the high genetic diversity of NTHi 
strains and high antigenic variability of surface-exposed antigens [8, 9]. Therefore, there is an 
urgent need for developing alternate therapeutic strategies for treating NTHi infections. Previous 
studies have shown that NTHi up-regulates MUC5AC transcription via Toll-like receptor (TLR)-
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dependent activation of p38 MAPK and transcription factor AP-1 [10]. Due to the involvement 
of p38 MAPK in multiple cellular processes, therapies inhibiting it can have detrimental effects 
in the long-term. Thus identification of novel therapeutic strategies with minimal side effects is 
strongly desired. 
Curcumin, a yellow pigment derived from the rhizome Curcuma longa, is reported to 
possess a broad range of pharmacological effects, including antioxidant, anti-tumor, anti-
inflammatory, anti-microbial and anti-diabetic properties [11]. Curcumin does not present a 
dose-limiting toxicity, thereby potentiating long-term usage with minimal side effects [12]. 
Curcumin is classified as “generally recognized as safe (GRAS)” by the United States Food and 
Drug Administration. Despite its pleiotropic effects on a multitude of diseases, poor 
bioavailability presents a major limitation for curcumin usage [12]. We recently reported the 
inhibitory effect of curcumin on NTHi-induced neutrophil recruitment in a mouse model of OM 
[13]. However, the effect of curcumin on regulating MUC5AC mucin, a major contributor of 
OM pathology, remains to be evaluated. 
In this study, we demonstrate that curcumin inhibits NTHi-induced MUC5AC expression 
in vitro and in vivo in middle ear epithelial cells. Curcumin inhibited MUC5AC expression via 
inhibition of p38 MAPK via induction of negative regulator, MKP-1. Thus, our study provides 
evidence for the anti-inflammatory potential of curcumin in treating NTHi-induced OM by 
suppressing MUC5AC mucin overproduction. 
3.3 Materials and methods  
3.3.1 Reagents and antibodies  
Curcumin was purchased from Sigma. SB203580 was purchased from Enzo Life 
Sciences. Antibodies for MUC5AC (sc-21701) and MKP-1 (sc-370) were purchased from Santa 
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Cruz Biotechnology. Anti-mouse HRP-linked antibody (#7076) was purchased from Cell 
Signaling Technology. Anti-mouse Alexa 488-conjugated antibody (A11029), anti-rabbit Alexa 
488-conjugated antibody (A21206) were purchased from Life Technologies.  
3.3.2 Cell culture 
Human middle ear epithelial cells (HMEECs) were grown and maintained in DMEM 
(Cellgro) supplemented with BEGM SingleQuots (Lonza), 10% fetal bovine serum and 100U/ml 
penicillin and 100 µg/ml streptomycin (Gibco) in a humidified 5% CO2 atmosphere at 37 °C. 
3.3.3 Bacterial strains and culture conditions 
Clinical isolates of NTHi strains 12, 2627, 9274 were used for this study [14, 15]. NTHi 
was prepared as described previously [13]. For in vitro experiments NTHi re-suspended in 
DMEM and used at a multiplicity of infection (MOI) of 50. For in vivo experiments, NTHi was 
re-suspended in isotonic saline and used at a concentration of 5 x 107  CFU per mouse. 
3.3.4 Plasmids, transfection and luciferase assay 
The expression plasmids, for constitutively active (CA) forms of MKK3 (MKK3b (E)), 
MKK6 (MKK6b (E)), dominant negative forms of p38a (fp38a (AF)), p38b (fp38b2 (AF)) have 
been described previously [16]. MUC5AC-Luc luciferase reporter vector, AP-1 mutants of 
MUC5AC-Luc luciferase reporter vectors have been described previously [17]. Myc-MKP-1 
overexpression plasmid has been described previously [13]. All transient transfections were 
performed using TransIT-LT-2020 transfection reagent (Mirus) according to the manufacturer’s 
protocol. Cells were assayed 48 h after transfection. Empty vector was transfected as a control. 
pRL-Renilla luciferase vector was from Promega Luciferase activity was measured using Dual-
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Luciferase Reporter Assay System (Promega). MUC5AC luciferase activity was normalized to 
Renilla activity. 
3.3.5 RNA-mediated interference 
The human pSUPER-shMKP-1 knockdown construct as described previously [18] was 
transfected using TransIT-LT-2020 transfection reagent (Mirus) according to manufacturer’s 
protocol. Cells were assayed 48 h after transfection. 
3.3.6 Real-time quantitative PCR (Q-PCR) analysis 
Total RNA was extracted with TRIzol reagent, according to manufacturer's protocol (Life 
Technologies). TaqMan reverse transcription reagents were used to perform Reverse 
transcription reaction (Applied Biosystems). Real-time quantitative PCR reactions were 
performed using Fast SYBR Green Master Mix (Applied Biosystems) and amplified, quantified 
with StepOnePlus Real-Time PCR system (Applied Biosystems). Relative quantities of mRNAs 
were calculated using the comparative Ct method and were normalized to control; human 
Cyclophilin or mouse glyceraldehyde-3-phosphate (GAPDH). Human (h) and mouse (m) primer 
sequences for hMUC5AC, hMKP-1, hCyclophilin, mMUC5AC, mGAPDH primer sequences 
were previously described [18].  
3.3.7 Enzyme-linked immunosorbent assay (ELISA) 
HMEECs were stimulated with NTHi for 12h. Cell-culture media was harvested and 
centrifuged at 12,000 x g for 10 min to precipitate cell debris. Supernatants were assayed by 
direct ELISA method as described previously [19]. OD was measured using Benchmark Plus 
microplate spectrophotometer. MUC5AC protein concentration in the supernatant was 
determined by normalizing to the control group. 
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3.3.8 Immunofluorescence staining 
Cells were grown on 18 mm round glass coverslips (VWR). Following NTHi stimulation, 
cells were fixed with 4% paraformaldehyde, followed by incubation with primary antibodies at 1 
: 100 − 1 : 400 dilutions. Alexa-conjugated secondary antibody was used to detect the primary 
antibody. The coverslips were mounted onto glass slides using VECTASHIELD HardSet 
Antifade Mounting Medium with DAPI (Vector). Images were recorded with fluorescence 
microscopy system (BZ-X710 Microscope and BZ-X Viewer, BZ-X Analyzer imaging system, 
Keyence). 
3.3.9 Mice and Animal Experiments 
C57BL/6 mice (Jackson Laboratories) were employed. Anesthetized mice were 
inoculated with NTHi via the trans-tympanic route. For inhibition studies, mice were injected 
intraperitoneally (i.p) with curcumin (50 mg/kg) 1 h prior or 1 h post-NTHi inoculation. Total 
RNA was extracted from the dissected mice middle ear. All animal experiments were carried out 
following the guidelines approved by The Institutional Animal Care and Use Committee at 
Georgia State University. 
3.3.10 Statistical analysis 
All experiments were repeated at least three independent times. Data are represented as 
mean ± standard deviation (s.d.). Statistical significance was assessed with unpaired student's t-
test for data with two conditions (k = 2), ANOVA (followed by Tukey’s post hoc) for data with 
more than two conditions (k > 2), using SPSS 22 statistics software (IBM). *p < 0.05 was 
considered statistically significant. 
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3.4 Results and Discussion 
3.4.1 Curcumin suppresses NTHi-induced MUC5AC expression in middle ear epithelial cells 
in vitro and in vivo. 
Curcumin has been reported to suppress neutrophil migration, an early inflammatory 
response to NTHi infection in OM model [13]. To further evaluate the anti-inflammatory 
potential of curcumin in treating OM, we determined the effect of curcumin on MUC5AC mucin 
expression, a major contributor of OM pathogenesis.  Curcumin pre-treatment inhibited NTHi-
induced MUC5AC mRNA expression in a dose-dependent manner in HMEECs (Fig. 3.1A). 
Curcumin also inhibited MUC5AC mRNA expression in HMEECs stimulated with other 
common OM-causing NTHi strains 2627 and 9274 (Fig. 3.1B), suggesting the generalizability of 
the inhibitory effect of curcumin on MUC5AC mucin. We next determined if curcumin inhibits 
MUC5AC transcription by determining the activity of MUC5AC promoter-driven luciferase 
vector. Curcumin suppressed NTHi-induced MUC5AC transcription (Fig. 3.1C). The inhibitory 
effect of curcumin on MUC5AC protein levels was also confirmed by ELISA (Fig. 3.1D) and by 
immunofluorescence staining (Fig. 3.1E). Consistent with in vitro findings, curcumin pre-
treatment inhibited MUC5AC mRNA expression in the middle ear of mice inoculated with NTHi 
(Fig. 3.1F). Therefore, these data suggest that curcumin inhibits NTHi-induced MUC5AC mucin 
expression in middle ear epithelial cells in vitro and in vivo.  
3.4.2 Curcumin suppresses NTHi-induced MUC5AC expression via inhibition of p38 
MAPK. 
Next, we sought to determine the mechanism by which curcumin inhibits MUC5AC 
expression. p38 MAPK signaling pathway has been shown to be critical in mediating NTHi-
induced inflammatory responses. We previously reported that NTHi up-regulates MUC5AC 
expression via activation of p38 MAPK [10]. In a recent study, we showed that curcumin inhibits 
	 70 
NTHi-induced p38 phosphorylation [13]. Thus, we determined if curcumin inhibits MUC5AC 
expression via suppression of p38 activation. MAPK kinases MKK3 and MKK6 are upstream 
activators of p38 MAPK. MKK3 activates p38a only, whereas MKK6 activates both p38a and 
p38b isoforms. Overexpression of constitutively active (CA) forms of MKK3 (MKK3-CA) or 
MKK6 (MKK6-CA) markedly induced MUC5AC expression, while curcumin suppressed 
MKK3-CA or MKK6-CA-induced MUC5AC expression (Fig. 3.2A). To determine if curcumin 
inhibits MUC5AC expression via suppression of p38, we used multiple approaches. Pre-
treatment with curcumin or SB203580 (a specific inhibitor of p38 activation) alone markedly 
suppressed NTHi-induced MUC5AC expression in HMEECs. However, co-treatment of 
curcumin along with SB203580 did not further suppress MUC5AC expression (Fig. 3.2B). 
Consistent with the p38 inhibitor data, curcumin failed to suppress NTHi-induced MUC5AC 
expression further in HMEECs transfected with dominant negative (DN) mutant forms of p38; 
p38a-DN and p38b-DN (Fig. 3.2C). 
AP-1 is one of the major transcription factors downstream of p38 MAPK. Sequence 
analysis of MUC5AC promoter region revealed the presence of two AP-1 transcription factor 
binding sites located between base pairs -3576/-3570 and -3535/-3529. Selective mutagenesis of 
these sites showed that the distal AP-1 site (-3576/-3570) is necessary for up-regulation of 
MUC5AC transcription, while the proximal AP-1 site (3535/-3529) is involved in the negative 
regulation of MUC5AC transcription [17]. Therefore to further determine which one of these 
AP-1 sites in involved in curcumin-mediated inhibition of MUC5AC transcription, we employed 
wild-type MUC5AC promoter, distal AP-1 mutant MUC5AC promoter and proximal AP-1 
mutant MUC5AC promoter containing luciferase vectors. Curcumin pre-treatment suppressed 
NTHi-induced transcription of both wild-type and proximal AP-1 mutant MUC5AC promoter 
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constructs, while curcumin did not further inhibit transcription of distal AP-1 mutant MUC5AC 
promoter (Fig. 3.2D). These findings suggest that curcumin inhibits MUC5AC transcription via 
inhibiting the positive AP-1 (distal site) pathway. Together these data suggest that curcumin 
suppresses NTHi-induced MUC5AC expression via inhibition of MKK3/6-dependent activation 
of p38 MAPK. 
3.4.3 Curcumin inhibits NTHi-induced MUC5AC expression via up-regulation of MKP-1 
phosphatase. 
MAP Kinase Phosphatase-1 (MKP-1) has been shown to be a key negative regulator of 
inflammation via dephosphorylation of MAPKs. We previously reported that MKP-1 is a 
negative regulator of NTHi-induced MUC5AC expression via inhibition of p38 MAPK [20].  We 
previously demonstrated that curcumin markedly enhanced NTHi-induced MKP-1 expression at 
mRNA and protein levels. The same study showed that curcumin suppressed p38 MAPK 
phosphorylation via up-regulation of MKP-1 expression [13]. Therefore, it is likely that 
curcumin suppresses NTHi-induced MUC5AC expression via a similar mechanism. We first 
confirmed that curcumin increases NTHi-induced MKP-1 expression by immunofluorescence 
staining (Fig. 3.3A). Next, we confirmed the role of MKP-1 in MUC5AC regulation. MKP-1 
overexpression suppressed NTHi-induced MUC5AC expression (Fig. 3.3B). Knockdown of 
endogenous MKP-1 with MKP-1 shRNA enhanced MUC5AC expression (Fig. 3.3C). Since 
curcumin up-regulates MKP-1 expression and MKP-1 is a negative regulator of MUC5AC 
expression, we sought to determine the role of MKP-1 in curcumin-mediated MUC5AC 
suppression. Depletion of MKP-1 with shMKP-1 rendered curcumin treatment ineffective in 
inhibiting NTHi-induced MUC5AC mRNA expression (Fig. 3.3D). Together, these data suggest 
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that curcumin inhibits NTHi-induced MUC5AC expression via an MKP-1 dependent 
mechanism. 
3.4.4 Post-infection administration of curcumin inhibits MUC5AC expression in middle ear 
epithelial cells in vitro and in vivo. 
Next, we sought to evaluate the therapeutic relevance of the inhibitory effect of curcumin 
on MUC5AC mucin in an NTHi-induced OM setting. Thus, we evaluated the effect of injecting 
curcumin post-NTHi infection, which resembles a clinically relevant context. Curcumin 
administration post-NTHi infection significantly suppressed NTHi-induced MUC5AC mRNA 
expression in vitro (Fig. 3.4A) and in vivo (Fig. 3.4B). Curcumin suppressed MUC5AC 
expression to the same extent under both pre-NTHi and post-NTHi infection conditions. Thus, 
these data suggest that curcumin is a potential therapeutic for treating NTHi-induced MUC5AC 
mucin overproduction as seen in OM. 
In summary, our study demonstrates that curcumin inhibits NTHi-induced MUC5AC 
expression in vitro and in vivo. Curcumin suppressed NTHi-induced MUC5AC expression by 
inhibition of p38MAPK via up-regulation of MKP-1 (Fig. 3.4C). Curcumin treatment post-NTHi 
infection also inhibited MUC5AC expression in a mouse model of OM, suggesting the clinical 
relevance of our findings. Thus, our study reports for the first time the efficacy of curcumin in 
treating NTHi-induced MUC5AC mucin overproduction. Further studies targeted towards 
increasing the bioavailability and development of ototopical drug delivery systems will be of 
clinical significance in treating OM. The insights of this study may have broader applications in 
the context of other chronic inflammatory conditions. 
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Figure 3.1 Curcumin suppresses NTHi-induced MUC5AC expression in middle ear epithelial 
cells in vitro and in vivo 
(A) HMEECs were pre-treated with 10, 20 or 50 µM curcumin for 1 h, followed by NTHi for 5 h, and MUC5AC 
mRNA expression was measured. (B) HMEECs were pre-treated with 20 µM curcumin for 1 h, followed by NTHi 
strains 12, 2627 or 9274 for 5 h, and MUC5AC mRNA expression was measured. (C) HMEECs were transfected 
with MUC5AC promoter-driven luciferase vector. Cells were pre-treated with 20 µM curcumin for 1 h, followed by 
stimulation with NTHi for 5 h. MUC5AC promoter-driven luciferase activity was measured. (D) HMEECs were 
pre-treated with 20 µM curcumin for 1 h, followed by stimulation with NTHi for 12 h, and MUC5AC protein levels 
in cell culture supernatants was measured by ELISA. (E) HMEECs were pre-treated with 20 µM curcumin for 1 h; 
followed by NTHi stimulation for 12 h. MUC5AC protein (Alexa 488) was visualized by immunofluorescence 
staining. DAPI, nuclear stain. Magnification: 400✕. (F) Mice were administered with 50 mg/kg (i.p) curcumin 1 h 
prior trans-tympanic inoculation of NTHi. 6 h after NTHi inoculation MUC5AC mRNA expression in dissected 
middle ear was measured. Data are mean ± s.d. (n=3). A; *p < 0.05, ANOVA (Tukey's posthoc). B-D, F; *p < 0.05, 
t-test. Data are representative of three or more independent experiments. 
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Figure 3.2 Curcumin suppresses NTHi-induced MUC5AC expression via inhibition of p38 
MAPK 
(A) HMEECs were transfected with Mock, MKK3 - CA or MKK6 - CA plasmids. Cells were treated with 20 µM 
curcumin for 1 h, and MUC5AC mRNA expression was measured. (B) HMEECs were pre-treated with 20 µM 
curcumin and 10 µM SB203580 for 1 h, followed by stimulation with NTHi for 5 h, and MUC5AC mRNA 
expression was measured (C) HMEECs were transfected with Mock, p38a - DN, or p38b - DN plasmids. Cells were 
pre-treated with curcumin (20 µM) for 1 h, followed by NTHi stimulation for 5 h and MUC5AC mRNA expression 
was measured. (D) HMEECs were transfected with wild-type MUC5AC promoter, distal AP-1 mutant MUC5AC 
promoter or proximal AP-1 mutant MUC5AC promoter containing luciferase vectors. Cells were pre-treated with 20 
µM curcumin for 1 h, followed by NTHi stimulation for 5 h. MUC5AC promoter-driven luciferase activity was 
measured. Data are mean ± s.d. (n=3). B-D; *p < 0.05, ANOVA (Tukey’s post hoc). Data are representative of three 
or more independent experiments. 
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Figure 3.3 Curcumin inhibits NTHi-induced MUC5AC expression via up-regulation of MKP-1 
phosphatase 
 (A) HMEECs were pre-treated with curcumin (20 µM) for 1 h; followed by NTHi stimulation for 1 h. MKP-1 
protein (Alexa 488) was visualized by immunofluorescence staining. DAPI, nuclear stain. Magnification: 400✕. (B, 
C) HMEECs were transfected with (B) Mock or myc-MKP-1, (C) Mock or MKP-1 shRNA. Cells were stimulated 
with NTHi for 5 h, and MUC5AC mRNA expression was measured. MKP-1 knockdown was confirmed by Q-PCR. 
(D) HMEECs were transfected with Mock or MKP-1 shRNA plasmid. Cells were pre-treated with 20 µM curcumin 
for 1 h, followed by NTHi stimulation for 5 h, and MUC5AC mRNA expression was measured. B, C; *p < 0.05, t-
test. D; *p < 0.05, ANOVA (Tukey’s post hoc). n.s., not significant. Data are representative of three or more 
independent experiments. 
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Figure 3.4 Post-infection administration of curcumin inhibits MUC5AC expression in middle ear 
epithelial cells in vitro and in vivo 
(A) HMEECs were pre-treated with curcumin (20 µM) 1 h prior NTHi stimulation or post-treated with curcumin (20 
µM) 1 h after NTHi stimulation. 5 h after NTHi stimulation MUC5AC mRNA expression was measured. (B) Mice 
were administered with 50 mg/kg (i.p) curcumin 1 h prior trans-tympanic inoculation of NTHi or were post-
administered with 50 mg/kg (i.p) curcumin 1 h post-NTHi inoculation. 6 h after NTHi inoculation MUC5AC mRNA 
expression in dissected middle ear was measured. (C) Schematic representation illustrating that curcumin suppresses 
NTHi-induced MUC5AC expression via MKP-1-dependent inhibition of p38 MAPK. A, B; *p < 0.05, ANOVA 
(Tukey’s post hoc). n.s., not significant. Data are representative of three or more independent experiments. 
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4.1 Introduction 
Protein ubiquitination is one of the important post-translational modification (PTM) in 
the control of many biological processes including immune responses. Ubiquitin (Ub), a 76 
amino acid protein is covalently attached to other proteins via an isopeptide bond formed 
between the glycine residue in its C-terminal and the -amino group of the lysine (K) residue on 
its substrate. Ubiquitination is carried out by the sequential activity of three enzymes. Ub-
activating enzyme (E1) catalyzes the formation of a thioester bond between the cysteine residue 
in its active center and the C-terminal glycine on the Ub molecule. Activated Ub gets transferred 
to an Ub-conjugating enzyme (E2) via a similar thioester bond formation. These two steps are 
ATP-dependent. Next, an Ub-ligase (E3) binds to both E2 and the substrate protein and 
facilitates the transfer of Ub from E2 to the internal lysine residue on the substrate. In addition to 
monoubiquitination, a protein can also undergo polyubiquitination. Formation of 
polyubiquitination chains follows the same pattern with the ubiquitin’s C-terminal glycine 
(Gly76) conjugated to the internal lysine residues within the ubiquitin protein. The presence of 7 
internal lysine residues (K6, K11, K27, K29, K44, K48 and K63) contributes to the diversity of 
the ubiquitination chains. While different Ub chain types adopt different conformations that 
promote interactions with linkage-specific Ub-binding domains, the physiological roles of the Ub 
linkages (with an exception to K48 and K63-linked chains), remains to be understood [1, 2].   
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The presence of K48-linked Ub chains on substrate proteins has been long identified to 
be responsible for recognition and degradation by the proteasome [3]. The Ub-tagged substrate 
protein is degraded by the proteasome, while the free Ub is released [4]. In contrast K63-linked 
Ub chains exert a non-degradative effect on the proteins as seen in cell signaling cascades. The 
presence of K63-linked Ub chains on the proteins alters the function of the proteins in a 
reversible manner. K63-linked Ub chains can alter the interaction of the substrate protein with 
other proteins. K63-linked Ub has been widely known to render the proteins as scaffold/adaptors 
molecules that serve by promoting protein-protein interactions and thereby enhances the activity 
of the signaling cascade [1, 5]. MKP-1 protein has been shown to undergo various PTMs such as 
phosphorylation, acetylation, oxidation and K48-linked ubiquitination in response to stimuli [6-
9]. However, the molecular mechanism of K63-linked polyubiquitination of MKP-1 remains 
largely unknown.  
In this study, we demonstrate for the first time that NTHi-induces K63-linked 
polyubiquitination of MKP-1 in vitro and that the anti-inflammatory compound curcumin 
enhances K63-linked polyubiquitination, which could, in turn, promote MKP-1 activity.  
4.2 Methods and Materials 
4.2.1 Cell culture 
Human middle ear epithelial cells (HMEECs) were maintained in DMEM (Cellgro) 
supplemented with BEGM SingleQuots (Lonza), 10% fetal bovine serum and 100U/ml penicillin 
and 100 µg/ml streptomycin (Gibco). Cells were cultured at 37 °C in 5% CO2 atmosphere. 
4.3 Reagents and antibodies 
 Curcumin was purchased from Sigma. Antibodies for c-Myc (sc-40), HA (sc-805) and, 
a-tubulin (sc-69969), IgG (sc-3877) and Protein G Plus agarose beads (sc-2002) were purchased 
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from Santa Cruz Biotechnology. Antibodies for anti-mouse HRP-linked antibody (#7076) and 
anti-rabbit HRP-linked antibody (#7074) were purchased from Cell Signaling Technology. 
4.3.1 Bacterial strains and culture conditions 
Clinical isolates of NTHi strain 12 was used for this study [10, 11]. NTHi was prepared 
as described previously [12]. NTHi re-suspended in DMEM was used at a multiplicity of 
infection (MOI) of 50 for time as indicated. For evaluating the effect of curcumin on protein 
ubiquitination, cells were pre-treated with curcumin for 1 h prior to NTHi stimulation. 
4.3.2 Plasmids and transient transfection 
Myc-MKP-1 expression plasmid has been described previously. Expression plasmids 
pRK5-HA-WT Ub (ubiquitin with all lysine (K) residues intact), pRK5-HA-K48 (ubiquitin with 
only K48 residue), pRK5-HA-K63 (ubiquitin with only K63 residue) were purchased from 
Addgene. All transient transfections were performed using TransIT-LT-2020 transfection reagent 
(Mirus) according to the manufacturer’s protocol. Cells were assayed 48 h after transfection. 
4.3.3 Ubiquitination Assay 
Cells were washed, harvested and collected in 1ml PBS, followed by centrifugation at 
6000 × g for 2 min. The “cell lysate” pellet was dissolved in 100µl denaturation buffer 
containing 20 mM HEPES, 150 mM NaCl, 1 % SDS. 5 % glycerol, 10 mM β-mercaptoethanol, 
10 mM NEM (N-ethylmaleimide), 1 mM Na3VO4 and protease inhibitor cocktail and boiled for 
10min to denature the noncovalent interactions. Samples were then diluted in 900µl dilution 
buffer containing 20 mM HEPES, 150 mM NaCl, 2.2 mM EDTA, 1.1 % Triton-X, 5 % glycerol, 
10 mM NEM (N-ethylmaleimide), 1 mM Na3VO4 and protease inhibitor cocktail. Diluted 
samples were used for immunoprecipitation and western blot analysis. 
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4.3.4 Immunoprecipitation 
 Cell lysates were incubated with 1µg of corresponding primary antibody overnight at 
4°C, followed by incubation with Protein G Plus agarose beads for 2 h. The beads were washed 
for 4 times, followed by suspension in sample loading buffer.  
4.3.5 Western Blot Analysis 
Immunoprecipitates and cell lysates were separated on 10% SDS-PAGE gel, transferred 
to polyvinylidene difluoride (PVDF) membrane. The membrane was blocked with blocking 
buffer (TBS containing 0.1% Tween 20 (TBS-T) and 5% nonfat dry milk). After 3 washes with 
TBS-T, the membrane was incubated overnight with primary antibodies at 1 : 1,000 − 1 : 2,000 
dilutions in antibody dilution buffer (TBS-T containing 5% BSA) at 4 °C. After 3 washes with 
TBS-T, the membrane was incubated with corresponding secondary antibody at 1 : 5,000 
dilution in blocking buffer for 1 h. After 3 washes with TBS-T, the proteins were visualized 
using Amersham ECL Prime Detection Reagent (GE Healthcare). 
4.4 Results 
4.4.1 NTHi induces K63-linked polyubiquitination of MKP-1 
Among all the major post-translational modifications, ubiquitination of the host’s signal 
transduction molecules is an important regulatory mechanism to ensure tight control of the 
immune responses [5]. Since MKP-1 is a major negative regulator of inflammation, we initially 
sought to determine if MKP-1 undergoes polyubiquitination in response to NTHi stimuli. NTHi 
induced polyubiquitination of MKP-1 in a time-dependent manner in HMEECs transfected with 
Myc-MKP-1 and HA-WT Ub overexpression vectors (Fig. 4.1A). To further identify the nature 
of the polyubiquitination chains on MKP-1, we employed HA-K48 Ub and HA-K63 Ub 
expression vectors. NTHi predominantly induced K63-linked polyubiquitination of Myc-MKP-1 
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compared to K48-linked polyubiquitination (Fig. 4.1B). Taken together these data demonstrate 
for the first time that MKP-1 protein undergoes K63-linked polyubiquitination in response to 
NTHi infection.    
4.4.2 Curcumin enhances NTHi-induced K63 polyubiquitination of MKP-1 
Curcumin has been previously reported to enhance the mRNA and protein expression of 
the negative regulator MKP-1 [12]. However, its role in regulating MKP-1 protein activity is 
unknown. Curcumin pre-treatment enhanced NTHi-induced polyubiquitination of MKP-1 in 
HMEECs transfected with Myc-MKP-1 and HA-WT Ub in a time-dependent manner (Fig. 
4.2A). Since NTHi predominantly induced K63-linked polyubiquitination of MKP-1, we 
evaluated the effect of curcumin on K63-linked polyubiquitination of MKP-1. Consistent with 
the WT polyubiquitination data, curcumin pre-treatment enhanced NTHi-induced K63-linked 
polyubiquitination of MKP-1 (Fig. 4.2B). Since K63-linked polyubiquitination has been widely 
reported to regulate the activity of the target proteins, these data suggest that curcumin not only 
up-regulates MKP-1 expression, but also regulates its activity by enhancing K63-linked 
polyubiquitination.  
4.5 Discussion 
Despite the significant role of MKP-1 in modulating immune responses, the mechanisms 
underlying its activity are unclear. Several immunosuppressive agents such as glucocorticoids, 
phosphodiesterase (PDE) inhibitors, vinpocetine, resveratrol, and curcumin mediate their 
inhibitory effects via MKP-1 [12-16]. Therefore, understanding the mechanism of action of these 
drugs on regulating MKP-1 activity is critical for developing alternative therapeutics. Here, we 
show that NTHi induces K63-linked polyubiquitination of MKP-1. We also demonstrate that 
curcumin enhances NTHi-induced K63-polyubiquitination of MKP-1 (Fig. 4.3).   
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The importance of K63 Ub linkages in mounting an appropriate immune response is 
widely known [17]. However, the role of K63 polyubiquitination in negatively regulating 
immune responses is not entirely understood. We show for the first time that MKP-1, a negative 
regulator of p38 MAPK undergoes K63-linked polyubiquitination. This finding is of particular 
significance due to the increasing importance of modulating PTMs of signaling proteins in 
regulating immune responses.  
Curcumin has been previously reported to suppress NTHi-induced up-regulation of 
inflammatory mediators such as CXCL5 and MUC5AC mucin via MKP-1. Curcumin up-
regulated MKP-1 expression at both mRNA and protein levels. Increased levels of MKP-1, led to 
inhibition of p38 MAPK activation, resulting in suppression of inflammation [12]. Here we 
report for the first time a new mechanism of action of curcumin on MKP-1. Curcumin enhanced 
K63-linked polyubiquitination of MKP-1. K63-linked polyubiquitination mediates non-
degradative molecular functions such as protein-protein interactions, protein trafficking and 
regulation of signal transduction events. Therefore, our finding that curcumin enhances K63-
linked polyubiquitination of MKP-1 suggests that curcumin also promotes MKP-1 activity. K63 
Ub chains on MKP-1 could increase the affinity of MKP-1 to its substrate p38 MAPK, thereby 
increasing MKP-1’s phosphatase activity. K63-linked polyubiquitination of MKP-1, could 
increase MKP-1 protein’s half-life and prolong the duration of immunosuppression. The 
presence of K63-linked Ub on MKP-1 could pre-empt K48-linked Ub chains from assembling on 
it, and thereby protecting it from proteasomal degradation.  
Further studies identifying the specific lysine residues on MKP-1 undergoing K63-linked 
polyubiquitination and the E3 ligase(s) involved in promoting K63-linked polyubiquitination are 
needed. Understanding the specific roles of ubiquitination and the ubiquitination enzymes in 
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MKP-1 regulation could help identify novel drug targets for counteracting overactive immune 
responses. 
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Figure 4.1 NTHi induces K63-linked polyubiquitination of MKP-1  
(A) HMEECs were co-transfected with Myc-MKP-1 and HA-WT Ub expression vectors. Cells were stimulated with 
NTHi for 1, 2, 3 and 4 h. Cell lysates were immunoprecipitated (IP) with c-Myc antibody. Polyubiquitination in the 
immunoprecipitates was visualized by immunoblotting (IB) using anti-HA antibody. (B) HMEECs were co-
transfected with Myc-MKP-1 and HA-K48 Ub or HA-K63 Ub expression vectors. Cells were stimulated with NTHi 
for 2 and 3 h. Cell lysates were immunoprecipitated (IP) with c-Myc antibody. K48-, K63-linked polyubiquitination 
in the immunoprecipitates was visualized by immunoblotting (IB) using anti-HA antibody. 
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Figure 4.2 Curcumin enhances K63-linked polyubiquitination of MKP-1 
(A) HMEECs were co-transfected with Myc-MKP-1 and HA-WT Ub expression vectors. Cells were pre-treated 
with curcumin (20 µM) for 1 h, followed by stimulation with NTHi for 1, 2, 3 and 4 h. Cell lysates were 
immunoprecipitated (IP) with c-Myc antibody. Polyubiquitination in the immunoprecipitates was visualized by 
immunoblotting (IB) using anti-HA antibody. (B) HMEECs were co-transfected with Myc-MKP-1 and HA-K63 Ub 
expression vectors Cells were pre-treated with curcumin (20 µM) for 1 h, followed by stimulation with NTHi for 2 
and 3 h. Cell lysates were immunoprecipitated (IP) with c-Myc antibody. K48-, K63-linked polyubiquitination in the 
immunoprecipitates was visualized by immunoblotting (IB) using anti-HA antibody. 
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Figure 4.3 Schematic representation of curcumin mediated up-regulation of K63-linked 
polyubiquitination of MKP-1 
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5 CONCLUSION 
OM is the most common childhood bacterial infection [1, 2] with more than 700 million 
ear infections in the US each year, resulting in approximately 30 million doctor visits each year 
and 5 billion dollars in patient care. OM frequently leads to conductive hearing loss, affecting 
children during the crucial period of speech and language development [3, 4]. NTHi represents 
the cause of approximately one-third episodes of OM. Current therapies for OM involve the use 
of analgesics and antipyretics for symptomatic treatment [5]. Though these medications are 
effective during certain stages of the disease, prolonged usage poses the risk of serious side 
effects due to unknown “off-targets” and weakened immune system. Decongestants, 
antihistamines, and corticosteroids have not been effective in treating OM [6]. Prophylactic use 
of antibiotics has rendered over 80% of the NTHi strains drug-resistant [7, 8]. Also, development 
of vaccines against NTHi remains a challenge due to the high genetic diversity of NTHi strains 
and high antigenic variability of surface-exposed antigens [9, 10]. Thus, there is an urgent need 
for developing alternative therapeutics for OM with increased efficiency and safety.  
During infection, epithelial cells act as the first line of defense by secreting numerous 
pro-inflammatory mediators including chemokines and mucus. Chemokines mainly act by 
recruiting neutrophils to the site of infection. While the appropriate neutrophil response is critical 
for the removal of the invading pathogen, excess inflammation can lead to tissue damage and 
perpetuate inflammation as seen in OM [11-14]. Similarly, mucus production represents a 
protective innate defense mechanism to protect and lubricate the epithelium and trap invading 
pathogens for removal by the mucociliary clearance system [15]. However, in chronic infections, 
excess mucin impairs the mucociliary clearance system, resulting in mucus accumulation and 
poor function of the mucus-lined epithelial tracts and perpetuates inflammatory responses. While 
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mucin up-regulation is an important innate defense response of the host to infections in the 
middle ear, excess mucin can lead to impaired mucociliary clearance and conductive hearing loss 
as seen in OM [16]. Therefore, tight regulation of the intensity and duration of inflammatory 
responses is necessary. Thus, understanding the underlying molecular mechanisms leading to up-
regulation of inflammatory responses is critical for developing effective therapeutic strategies. 
Despite the importance of CXCL5 chemokine in mediating inflammation, the molecular 
mechanisms underlying its up-regulation in OM remains largely unknown. In Chapter 2 of this 
work, we showed that NTHi up-regulates CXCL5 expression by activating IKKβ-IκBα and p38 
MAPK pathways via NF-κB-nuclear translocation-dependent and -independent mechanism. 
Since NF-κB plays a central role in regulating immune responses as well as many physiological 
responses, inhibition of this signaling axis could have detrimental effects. Our finding, that 
NTHi-induces CXCL5 expression via more than one signaling pathway offers the flexibility to 
modulate CXCL5 expression without completely abrogating its expression. 
While mounting an appropriate inflammatory response against invading microbial 
pathogens is critical for the survival of the host, deregulated overactive inflammatory responses 
are detrimental to the host in the form of septic shock, lethality from inadequate responses and 
misdirected responses against host cells resulting in autoimmunity. Multiple proteins targeting 
the components of TLR-signaling to prevent the deleterious effects of overactive immune 
responses exist. These negative regulators modulate TLR signaling mainly via transcriptional 
repression and post-translational modifications. Among the numerous categories of negative 
regulators, MKP-1, a member of a class of dual specificity phosphatases collectively termed 
MAPK phosphatases, has been shown to be a key negative regulator of inflammatory responses 
via dephosphorylation and inactivation of MAPKs, including p38 [17, 18]. Here, in Chapter 2, 
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we demonstrate that MKP-1 is a negative regulator of NTHi-induced CXCL5 expression. MKP-
1 suppressed CXCL5 via targeting p38 MAPK activation, thereby suggesting that up-regulating 
MKP-1 expression could be a potential therapeutic strategy for regulating overactive 
inflammatory responses in OM.  
We previously demonstrated that dexamethasone glucocorticoid inhibits p38 MAPK via 
up-regulation of MKP-1 [19]. Glucocorticoids owing to their potent immunosuppressive and 
anti-inflammatory effects have been in use for treating a gamut of diseases such as asthma, 
allergies, skin disorders, multiple sclerosis, immune disorders and cancer. However, prolonged 
usage has been reported to cause severe, sometimes irreversible side effects such as osteoporosis, 
endocrine and metabolic disorders, behavioral and cognitive changes, gastrointestinal tract 
complications, uveitis and weakened immune system [20], emphasizing the urgent need to 
identify safer alternatives to up-regulate negative regulators of inflammation.  
In Chapter 2, we provide evidence that curcumin, derived from Curcuma longa plant 
suppressed NTHi-induced CXCL5 expression in mouse model of OM. Curcumin markedly 
increased expression of negative regulator MKP-1. In the absence of MKP-1, curcumin failed to 
suppress CXCL5 expression, suggesting that curcumin mediates its inhibitory effect via negative 
regulator MKP-1. This finding is of particular translational significance due to the attractiveness 
of targeting overactive inflammation via induction of negative regulators [21]. From a clinical 
significance point of view, we observed that both pre-infection and post-infection treatment with 
curcumin not only inhibited NTHi-induced CXCL5 up-regulation but also suppressed PMN 
infiltration into the middle ear in a mouse model of OM. Curcumin treatment’s efficacy in 
inhibiting CXCL5 expression and PMN recruitment post-NTHi infection is particularly 
promising. Recently chemokines and chemokine receptors are increasingly considered as targets 
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for developing new drugs to control inflammation [22]. Our finding that curcumin suppresses 
NTHi-induced CXCL5 chemokine expression is of particular relevance in the current scheme of 
identifying chemokine-drug combinations to treat inflammation. 
Having established that anti-inflammatory potential of curcumin in inhibiting PMN-
infiltration into the middle ear in a mouse model of OM, we sought to extend this lead to 
examine the effect of curcumin on MUC5AC mucin expression, a major contributor of OM 
pathogenesis in Chapter 3. Interestingly, curcumin also suppressed NTHi-induced MUC5AC via 
up-regulation of MKP-1. Thus, our studies demonstrate for the first time the efficacy and 
pleiotropic anti-inflammatory action of curcumin by down-regulating expression of CXCL5 
chemokine and MUC5AC mucin to suppress NTHi-induced inflammatory responses in OM 
model.  
Immunosuppressive agents such as glucocorticoids, phosphodiesterase (PDE) inhibitors, 
vinpocetine, resveratrol, and curcumin mediate their inhibitory effects via MKP-1 [19, 23-26]. 
However, the mechanisms underlying their action are unclear. All proteins encounter some 
degree of PTMs during their lifetime. Amongst all the PTMs reported so far, protein 
phosphorylation and protein ubiquitination have emerged as major players in regulation signal 
transduction in response to environmental stimuli. Recent decades have seen a vast amount of 
research focused on identifying and characterizing protein kinases and phosphatases in signal 
transduction. However, protein ubiquitination is gaining prominence as one of the important 
PTM in the control of immune responses. The presence of 7 internal lysine residues (K6, K11, 
K27, K29, K44, K48 and K63) with the ubiquitin protein contributes to the diversity of the 
ubiquitination chains. The presence of K48-linked Ub chains on substrate proteins has been long 
identified to be responsible for recognition and degradation by the proteasome [27]. In contrast 
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K63-linked Ub chains exert a non-degradative effect on the proteins as seen in cell signaling 
cascades. The importance of K63 Ub linkages in mounting an appropriate immune response is 
widely known [28]. However, the role of K63 polyubiquitination in negatively regulating 
immune responses is not entirely understood. While MKP-1 protein has been shown to undergo 
various PTMs such as phosphorylation, acetylation, oxidation and K48-linked ubiquitination in 
response to stimuli [29-32] no mention about K63-linked polyubiquitination of MKP-1 exists. 
Therefore, in Chapter 4 we sought to determine K63-linked polyubiquitination status of MKP-1. 
We showed for the first time that MKP-1, a negative regulator of p38 MAPK undergoes K63-
linked polyubiquitination. This finding is of particular significance due to the increasing 
importance of modulating PTMs of signaling proteins to regulate immune responses.  
Curcumin has been previously reported to suppress NTHi-induced inflammation via up-
regulating MKP-1 expression at mRNA and protein levels. We next, sought to evaluate if 
curcumin can also affect K63-linked polyubiquitination of MKP-1. In Chapter 4 we report for 
the first time a new mechanism of action of curcumin on MKP-1. Curcumin enhanced K63-
linked polyubiquitination of MKP-1. K63-linked polyubiquitination mediates non-degradative 
molecular functions such as protein-protein interactions, protein trafficking and regulation of 
signal transduction events. Therefore, our finding that curcumin enhances K63-linked 
polyubiquitination of MKP-1 suggests that curcumin could also promote MKP-1 activity. K63-
linked polyubiquitination chain on MKP-1 could increase the affinity of MKP-1 to its substrate 
p38 MAPK, thereby increasing MKP-1’s phosphatase activity. Additionally, the presence of 
K63-linked polyubiquitination chains on MKP-1 could pre-empt K48-linked polyubiquitination 
chains from assembling on it and protect it from proteasomal degradation; extend MKP-1 
protein’s half-life and prolong the duration of immunosuppression. It should be noted that these 
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studies were performed under the presence of exogenously expressed MKP-1 protein. 
Additionally, this phenomenon needs to be confirmed by evaluating the polyubiquitination status 
of endogenous MKP-1 protein. The lack of MKP-1 antibody with high specificity hindered this 
investigation. Further studies identifying the specific lysine residues on MKP-1 undergoing K63-
linked polyubiquitination and the E3 ligase(s) involved in promoting K63-linked 
polyubiquitination are needed. Understanding the specific roles of ubiquitination and the 
ubiquitination enzymes in MKP-1 regulation could help identify novel drug targets for curcumin 
to counteract overactive immune responses.  
Curcumin is a nutraceutical that has been in use in South Asian countries for many 
centuries owing to its medicinal properties [33]. Curcumin can interact with a myriad of 
signaling molecules including transcription factors, protein kinases, growth factors, receptors, 
adhesion molecules, pro-inflammatory cytokines [34], thus explaining it pleiotropic therapeutic 
potential against a wide range of diseases. Curcumin does not present a dose-limiting toxicity, 
making it suitable for prolonged usage. Completed clinical trials reported usage of curcumin 
dosage ranging from 0.045 to 8 g/day. Currently, 38 clinical trials evaluating the efficacy of 
curcumin at a dosage ranging from 0.18 to 8 g/day for treating pathologies such as Alzheimer’s 
disease, diabetes, kidney disease, Crohn’s disease, cancer are underway [35]. Although curcumin 
holds promise as a safe drug for treating a gamut of conditions, its clinical application is 
hindered by many limitations. Poor absorption and bioavailability are a major concern. Orally 
administered curcumin undergoes conjugation and sulfation leading to the formation of curcumin 
glucuronide and curcumin sulfate in the intestines and liver. Curcumin administered via 
intravenous (i.v.) or intraperitoneal (i.p.) route undergoes reduction to form tetrahydrocurcumin, 
hexahydrocurcumin, and octahydrocurcumin. None of these metabolites are biologically active. 
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The low bioavailability of curcumin is due to its hydrophobic nature. Numerous approaches to 
increase curcumin bioavailability are currently underway. These include the (i) use of piperine as 
an adjuvant to protect against glucuronidation, (ii) liposomal curcumin, to increase uptake by cell 
membranes, (iii) curcumin nanoparticles, (iv) curcumin phospholipid complex and (v) structural 
analogs of curcumin. Another limitation of curcumin is its poor solubility in aqueous solvents.  
United States Food and Drug Administration classified curcumin as GRAS (generally 
recognized as safe), warranting its use as a supplement. [36]. Curcumin supplementation could 
be an effective disease preventive strategy due to its immunomodulatory activity [37]. Thus, 
curcumin's benefits could still be reaped while we wait for more conclusive clinical trials 
demonstrating its immense potential against multiple pathologies.  
To fully evaluate the potential of curcumin as a therapeutic for treating OM in a clinical 
setting, further studies focusing on the effect of curcumin on bacterial clearance and restoration 
of hearing loss are needed. Development of drug delivery systems in the form of eardrops and 
ototopical ointments could be of clinical benefit in treating OM.  Our study has only addressed 
the relationship between curcumin and one particular negative regulator MKP-1. However, it is 
likely that curcumin mediates its anti-inflammatory actions via other negative regulators of 
inflammation such as IRAK-M, MyD88s, and CYLD. Moreover, the cross talk between these 
negative regulators needs to be explored to identify potential targets for suppressing 
inflammation. Co-administration of curcumin along with other immunosuppressive agents such 
as resveratrol, dexamethasone, vinpocetine must be evaluated to maximize its therapeutic 
efficiency. The findings of this work could have applications in broader context to other bacterial 
infections and pathologies characteristic of chronic inflammation such as chronic obstructive 
pulmonary disease, cancer, tuberculosis and Alzheimer’s disease. Thus, curcumin meets several 
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if not all of the requirements of an alternative therapeutic with minimal side effects for treating 
NTHi-induced OM.  
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